',6&/2685(

5('$&7('[ZIP_CODE]&2/$0(1'0(17


&&6362

$3+$6(08/7,&(17(55$1'20,=( '3/$&(%2&21 752//(''28%/( 
%/,1'678'<2)7+(()),&$&<$1'6$) (7<2)$35(0,/$67&& ,1
68%-(&76:,7+02'(5$ 7(726(9(5(3/$48(3625,$6,62)7+(6&$/3

7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 

&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKD QFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV

7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHH QUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLR QHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQV DUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQU HSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWF RQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWF RQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\ DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRU W+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRU VDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWK HLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW
,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ


&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
,11
&$/3$/3
EHVKDUHGREHVKDUHGR
HUVDQGHUVDQGSDWLHSDWL
XODWLRQVUHTXDWLRQV
RUFRQWUDFWXRUFRQWUDFWX
FHUWDLQSDUWFHUWDLQSD
LQIRUPDWLRLQIRUPDW
&HOJHQHÂ¶VFROJHQHÂ¶VF
QFLSOHVQFLSOHV
VSDFHVSDFHPDLQPDLQ
DWLRQRILQGDWLRQRILQG
FRQILGHQWLDORQILGHQWL
QLGHQWLILDEQLGHQWLI
RPD\PDFRQWDFRQWD
JHQHUDWLQJJHQHUDWLQJ
DFKPHQWVDFKPHQWV
IWKHUHSRUWWKHUHSRUW
&&HOJHQHYHQHOJHQHY
WLQIRUPDWLRWLQIRUPDWLR
ERXWRXUYHQERXWRXUYH
DERXW&HOJDERXW&HOJ
DWKWWSZZKWWSZ
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 1 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879096] (CC-
[ZIP_CODE]) IN SUBJECTS WITH MODERATE TO SEVERE 
PLAQUE PSORIASIS OF THE SCALP
PROTOCOL NUMBER: CC-[ZIP_CODE]-SPSO-001
DATE FINAL: 29 Mar 2017
AMENDMENT 1 FINAL: [ADDRESS_879097] NUMBER: Not Applicable
IND NUMBER: IND 070270
SPONSOR NAME/ ADDRESS: Celgene Corporation
86 Morris AvenueSummit, NJ [ZIP_CODE]
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or 
consultant for review by [CONTACT_10825], your staff, and ethics committee/institutional 
review board.  The information contained in this document is regarded as 
confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by 
[CONTACT_27614].  Persons to whom the information is disclosed must be 
informed that the information is confidential and may not be further 
disclosed by [CONTACT_476].
CCI&(/*(1(11([ZIP_CODE],(7$5<,1)250$7,21lele
[ZIP_CODE]
ene Corporene Corpo
6 Morris A6 Morris A
Summit, Summit, 
NFIDENTNFIDENT
ou as an Inou as an I
ou, your stou, you
ormation cormation c
cept to the eept to the e
sed to anotsed to an
ions.  Persoions.  P
d that the inthat the in,(5,(
(1
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 2 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017MEDICAL MONITOR / EMERGENCY CONTACT [CONTACT_27615]:
Name:  
[CONTACT_1641]:  
           
Address: Celgene Corporation
                [ADDRESS_879098]
                Summit, NJ [ZIP_CODE]
Phone:  
E-mail:  
Note: The back-up 24-hour global emergency contact [CONTACT_184636](s) or Medical Monitor or designee for 
emergency calls.
Back-up 24-hour Global Emergency Contact [CONTACT_184637]: 
CCI[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
&(/*(1([ZIP_CODE],(7$5<,1)250$7,210$0$0$0$
25)21 er should er should
Medical MMedic
enter: nter: $57$$5PP
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 3 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017CELGENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_655120] [CONTACT_27616], I indicate I have reviewed this protocol and find its content to be 
acceptable.  
CCI[COMPANY_003]
&(/*(1([ZIP_CODE],(7$5<,1)250$7,210$0$
25ts content toconten
<,1<,1
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 4 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_27503]:_______________________________________
By [CONTACT_27616], I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaratio n of Helsinki, International Council for
Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations governing the conduct of clinical studies.
CCI&(/*(1([ZIP_CODE],(7$7$7$5<,1)250$7,210$0$5000
s studys study  at m atyy
, informed nformed
ocedures, inedures, i
national nationa C
nes, and locs, and lo
7$
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 5 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017COORDINATING PRINCIPAL INVESTIGATOR [INVESTIGATOR_655052], I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,210$0$0$0$0$0$0$
ICH GoodICH Good
t the studyhe stu
<,1<,1
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 6 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879099] (CC-[ZIP_CODE]) in Subjects with Moderate to Severe Plaque Psoriasis of 
the Scalp
Indication
The indication is moderate to severe plaque psoriasis of the scalp.
Objectives
Primary Objective
!To evaluate the clinical efficacy of apremilast 30 mg twice daily (BID) compared 
with placebo, in subjects with moderate to severe plaque psoriasis of the scalp, at Week 16
Secondary Objective(s)
!To evaluate the safety and tolerability of apremilast 30 mg BID compared with 
placebo, in subjects with moderate to severe plaque psoriasis of the scalp.
!To evaluate the effect of apremilast 30 mg BID compared with placebo on itch over 
the whole body caused by [CONTACT_655079]
!To evaluate the effect of apremilast 30 mg BID compared with placebo on itch 
associated with plaque psoriasis of the scalp
!To evaluate the onset of effect on itch over the whole body caused by [CONTACT_655080] 30 mg BID compared with placebo
!To evaluate the onset of effect on itch associated with plaque psoriasis of the scalp 
with apremilast 30 mg BID compared with placebo
!To evaluate the effect of apremilast 30 mg BID compared with placebo on health-
related quality of life (HRQoL)
Study Design
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the 
efficacy and safety of apremilast (CC-[ZIP_CODE]) in subjects with moderate to severe plaque psoriasis of the scalp.
Approximately 300 subjects will be randomized 2:[ADDRESS_879100] 16 weeks.  Ra ndomization will be stratified by [CONTACT_655081] (ScPGA) score (m oderate [3], severe [4]) to ensure balance 
between treatment arms with respect to baseline severity of scalp psoriasis.
!Subjects randomized to the apremilast [ADDRESS_879101] 16 weeks
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21D) comD) com pareparemmm
off the scalp the scalff
mg BID comg BID c
psoriasis opsoriasis o ff
compared wompared w
mg BID comg BID co
e scalpscalp
itch over thitch over t
mmpared wipared wimm tii
fect on itchfect on 
BID comD com papam
ect of apremect of apre
f lifelifeff (HRQ(HR
multmulticenter,icenter,
etyetyofofyy aprem apreff
he scalp.he scalp.
matelytely [ADDRESS_879102]
ysician Glosician Glo
between treetween tre
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 7 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017!Subjects randomized to the placebo treatment group will receive placebo tablets 
(identical in appearance to apremilast 30 mg tablets) orally twice daily for the first16 weeks
!All subjects will receive apremilast [ADDRESS_879103] of four phases:
!Screening Phase â€“ up to 35 days
!Double-blind Placebo-controlled Phase â€“ Weeks 0 to 16
Subjects will receive treatment with one of the following:  
âˆ€apremilast 30 mg tablets orally BID or
âˆ€placebo tablets (identical in appearan ce to apremilast 30 mg tablets) orally BID
!Apremilast Extension Phase â€“ Weeks 16 to 32
âˆ€All subjects will be switched to (or continue with) apremilast 30 mg BID at 
Week 16. All subjects will maintain this dosing through Week 32.
!Observational Follow-up Phase
âˆ€Four-week Post-treatment Observational Follow-up Phase for all subjects who 
complete the study or discontinue from the study early.
After all subjects have completed the Week 16 Visit (or discontinued from the study), a Week 16 
database lock will be performed; the primary data analysis will be conducted  
.  However, unblinded data will only be made available 
to select Sponsor and Contract Research Organization (CRO) team members involved with 
analysis of the data .  All other Sponsor, 
site, and CRO personnel directly involved with  the conduct of the study, will remain blinded to 
treatment assignments until the final database lock  at the conclusion of the study. At the end of 
the study, ie, when all subjects have also co mpleted (or have been di scontinued) the Apremilast
Extension Phase (Weeks 16 to 32) and the Observational Follow-up Phase, the final analysis will be performed and a final Clinical Study Report will be generated.
The study will be conducted in compliance wi th the International Council for Harmonisation 
(ICH) of Technical Requirements for Regist ration of Phar maceuticals for Human Use/G ood 
Clinical Practice (GCP) and applicable regulatory requirements.
Study Population
Adult subjects â‰¥ 18 years of age with moderate to severe plaque psoriasis (Psoriasis Area and 
Severity Index [PASI] â‰¥ 12, and Body Surface Area [BSA] â‰¥ 10%, and Static Physician Global 
Assessment [sPGA] â‰¥ 3 [moderate or greater]) who also ha ve moderate to severe plaque 
psoriasis of the scalp (Scalp Physician Global Assessment â‰¥ 3 [moderate or greater], and Scalp 
Surface Area â‰¥ 20%, and having had an inadequate response or intolerance to at least one topi[INVESTIGATOR_186691] [for example, potent or super potent topi[INVESTIGATOR_11930], vitamin D analogs, and 
combination products] for plaque psoriasis of the scalp).
CCICCI
CCI
CCI
voolved witlved wi
final databfinal datab
ts have alsts have als
16 to to 32) an32) an
al Clinical al Clinical
onducted ionducted i
ical Requirical Requir
tice (GCP)tice (GCP)
opulationulation
lt subjects lt subjects â‰¥
everitverity yInInded35,(7$5<,1)250$7,21blets)blet orallyorall
emilast milast 30 30
hrough Weough We
Foollollow-w-up u
m the studym the study
isit (or discsit (or dis
data analysidata analys
owever, unowever, un
OrganizatiOrganiz
AssessmeAssessme
sorisoriasas235
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 8 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879104] that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol, 
whichever is the later date.
Study Treatments
All IP will be provided in blister cards throughout  the entire study.  Apremilast will be provided 
as 10, 20, or [ADDRESS_879105] (IP) will be taken or ally twice daily, approximately 12 hours apart, 
without restriction of food or drink.  To mitigate potential gastrointestinal (GI) side effects, dose titration will be implemented in the first week of this study and at Week [ADDRESS_879106] 30 mg BID treatment.  
During Week 0 (Days 1 to 7), subjects will be dispensed dose titration blister cards with 10, 20, 
and [ADDRESS_879107] 7 days containing the titration 
supplies or matching placebo (see Table 4 : Treatment Schema for Dose Titration at Visit 2 
[Week 0]) which details the titration supplies from Day 1 to Day 7 in the Placebo-controlled 
Treatment Phase.  IP will be dispensed as indicated below: 
!Weeks 0 to 16: Double-blind, Placebo-controlled Treatment Phase: Apremilast 30 mg 
BID or placebo BID. 
âˆ€Week 0 to 1: subjects will be dose titrated as described above.
!Weeks 16 to 32: Apremilast Extension Phase: Apremilast 30 mg BID.
âˆ€Week 16 to 17: subjects will be dose titrated as described below.
At Visit 2 (Week 0), subjects who meet entry criteria will be randomized using a permuted block 
randomization in  parallel 2:[ADDRESS_879108] 30 mg BID or placebo, using a 
centralized Interactive Re sponse Technology (IRT). 
Starting at Week 16, all subjects will be switched to, or will continue with apremilast. Subjects 
originally randomized to placebo at Week [ADDRESS_879109] 30 mg BID at Week 16 (see Table 5 Treatment Schema for Dose Titration at Visit 7 [Week 16]) which details 
the titration supplies from Day [ADDRESS_879110]; dummy titration blister cards (dosing at 30 mg BID directly) will be used for subjects initially randomized to 
receive apremilast [ADDRESS_879111] 30 mg tablets which are to be taken twice daily.
Dose modifications are not permissible in this study.
CCI&(/*titi/*(1([ZIP_CODE],(7$5<,1)250$7,21provided ovided 
be provie provi dedde
hours aparhours apa
GI) side efGI) side ef
[ADDRESS_879112] t 77daydays cs c
hema for Dhema for
ayay 1 to Day 1 to Dayyy
d below: d below: 
ebobo--cocontntrolrol
ill be dose l be dose
milast Extenast Exten
subjects wsubjects 
cts who mes who m
eel l 2:1 to re2:[ADDRESS_879113]
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 9 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Overview of Key Efficacy Assessments
Primary Efficacy Assessment
!Scalp Physician Global Assessment (ScPGA)
Additional Efficacy Assessments
!Subjectâ€™s Assessment of Whole Body Itch numeric rating scale (NRS)
!Subjectâ€™s Assessment of Scalp Itch NRS
!!!
!
!Health-Related Quality of Life (HRQoL) questionnaires
âˆ€Dermatology Life Quality Index (DLQI)
âˆ€
Overview of Key Safety Assessments
Safety assessments will include:
!Adverse events (AE)
!12-lead electrocardiograms (ECG)
!Chest radiographs (CXR)
!Physical examinations
!Vital signs
!Pregnancy tests for females of childbearing potential (FCBP)
!Clinical laboratory tests
Statistical Methods
The study will randomize approximately 300 subjects in a 2:[ADDRESS_879114] 30 mg BID or 
placebo arms stratified by [CONTACT_655082] e (moderate [3], severe [4]). With this sample 
size, a chi-square test at the 2-sided 0.[ADDRESS_879115] 90% power to detect a 
minimum treatment difference of 18% (38% for apremilast 30 mg BID versus 20% for placebo) between the two arms for proportions of subjects achieving ScPGA response at Week 16 
(defined as ScPGA score of clear [0] or almost clear [1] with at least a 2 point reduction from 
baseline at Week 16).
Analyses for efficacy endpoints will be mainly on the intent-to-treat (ITT ) population, defined as 
all randomized subjects. Statist ical comparisons will be made b etween the two treatment arms.
CCICCI
CCI
CCI
CCI
CCI
CCI
&(/*(1ethodsthods
ywillwil randorandol
o armas sstratstra
, a chi, a chi -squasqua
minimum trminimum tr
between between 1([ZIP_CODE],(7$5<females of emales offf
toryryteststesyy,1)250$7,21
efinefin<,1
1(3(1(
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 10 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879116] 30 mg BID and placebo, will be compared using Cochranâ€“Mantelâ€“Haenszel 
(CMH) test adjusted by [CONTACT_655083]. Missing values at Week 16 will 
be imputed using the multiple imputation (MI) method as the primary analysis. Sensitivity 
analyses will be performed us ing the last observation carried forward (LOCF) method and the 
non-responder imputation (NRI) method. The binary secondary efficacy endpoints will be analyzed similarly as the primary endpoint. 
The analysis for the continuous secondary endpoint will be performed using the analysis of 
covariance (ANCOVA) model. The ANCOVA model will use the change from baseline as the dependent variable and will include treatment group and stratification factor as independent 
variables and the baseline value as a covariate variable.
All efficacy endpoints will be summarized by [CONTACT_655084]-controlled Phase 
(Weeks 0 to 16) and Apremilast Extension Phase (Weeks 16 to 32). When appropriate, 
exploratory endpoints at Week [ADDRESS_879117] one dose of IP. Safety will be assessed by [CONTACT_655085]-emergent adverse ev ents (TEAEs), laboratory tests, vital signs, 
and electrocardiogram (ECG) measurements. Data from safety assessments will be summarized 
descriptively for the Placebo-controlled Phase (Weeks 0 to 16) and the Apremilast Exposure 
Period. Adverse events will be classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. All TEAEs will be summarized by [CONTACT_9313], 
preferred term, severity, and relationship to IP.  TEAEs leading to death or to IP withdrawal and 
serious TEAEs will also be summarized and listed separately.  
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21he e 
e 
nalysis oalysis o f f 
baseline abaseline
r as indepenas indepe
PlPlaceboacebo --coc
)..When aphen a
CMH or ANMH o
populopulatatioion dn
ed by[INVESTIGATOR_530] b clinicclinicy
events (TEevents (TE
ata froata fro m m sa
se (Weeks se (Weeks 
using the Musing the M
TEAEs wilEAEs wil
nship to IPship to IP
marized andmarized an
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 11 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017TABLE OF CONTENTS
TITLE PAGE ..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1. INTRODUC TION ..................................................................................................17
1.1. Disease Background ...............................................................................................17
1.2. Compound B ackground ..........................................................................................17
1.3. Ration ale ................................................................................................................18
1.3.1. Study Rationale and Purpos e ..................................................................................18
1.3.2. Rationale for the Study De sign ...............................................................................18
1.3.3. Rationale for Dose, Schedule and Regimen Selectio n .............................................19
1.3.4. Rationale for Choice of  Compar ator....................................................................... 19
2. STUDY OBJECTIVES AND ENDPOINTS ...........................................................21
3. OVERALL STUDY DESIGN ................................................................................24
3.1. Overall Study  Desi gn..............................................................................................24
3.2. Study Duration for Subj ects....................................................................................25
3.3. End of Trial ............................................................................................................25
4. STUDY POPULATION .........................................................................................26
4.1. Number of Subjects ................................................................................................26
4.2. Inclusion Criteri a ....................................................................................................26
4.3. Exclusion Criteri a...................................................................................................27
5. TABLE OF EVENTS.............................................................................................30
6. PROCEDURES......................................................................................................33
6.1. Screening Period.....................................................................................................33
6.2. Treatment Pe riod....................................................................................................34
6.2.1. End of Tr eatment....................................................................................................35
6.3. Follow-up Period ....................................................................................................36
6.4. Efficacy Assessments .............................................................................................37
6.5. Safety Assessments .................................................................................................39
6.7. Patient Repor ted Outco mes.....................................................................................42
6.8. Photogra phy...........................................................................................................43
CCICCI
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,2177
.......1818
..................... 181
.........................
..........................
.........................
...........................
......................
.................
........................
..........................
...........................
......................
......................
...........................
NTSNTS .........
ES...........
g Periodg Period ....
ment Perioment Perio
nd of Treand of Trea
FoFollolloww
EffiEff
.5..5.,1)
&CI
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 12 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879118](s) ................................................................[ADDRESS_879119] Disposition .................................................................................................52
9.6. Efficacy Analysis ....................................................................................................52
9.6.1. Efficacy Evaluation for the Placebo-controlled Phase (Weeks 0 to 16) ....................52
[IP_ADDRESS]. Primary Efficacy  Endpoi nt......................................................................................52
[IP_ADDRESS]. Secondary Eff icacy Endpoi nts ................................................................................53
[IP_ADDRESS]. Multiplicity Adjustment..........................................................................................54
[IP_ADDRESS]. Exploratory Endpoints ............................................................................................55
[IP_ADDRESS]. Subgroup Analysis ..................................................................................................55
9.6.2. Efficacy Evaluation â€“ Apremilast Extension Phase (Weeks 16 to 32) ......................[ADDRESS_879120] Compliance (Tablets) .........................................................56
9.9.2. Concomitant Th erapy .............................................................................................56
CCICCI
&(/*(EffiEff
.7..7.
9.8..8.*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_879121]
EndpointEndpoint
ficacyficacy EndpEndpyy
tyty AAyydjustmdjus
oratoryoratory  End Endyy
ubgroup Aubgroup A
/*(
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 13 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879122] Program: Role of 
the Safety Ma nagement Team .................................................................................57
10. ADVERSE EV ENTS ..............................................................................................58
10.1. Monitoring, Recording and Re porting of Advers e Even ts .......................................58
10.2. Evaluation of A dverse Events.................................................................................58
10.2.1. Se riousness............................................................................................................. 58
10.2.2. Severity/I ntensi ty....................................................................................................[ADDRESS_879123]/Independent Ethics Committee Review and 
Approval ................................................................................................................ [ADDRESS_879124]/ Ethics Co mmittee ................[ADDRESS_879125] udy........................................................................................69
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21..[ADDRESS_879126] In
ConfiConfi
.5. PP
&13.6.3
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 14 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 201714. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] .....................................................70
14.1. Data/Docu ments .....................................................................................................[ADDRESS_879127] Retention ....................................................................................................70
15. QUALITY CONTROL AND QUALITY ASSURANCE ........................................72
15.1. Study Monitoring and S ource Data Veri ficatio n......................................................72
15.2. Audits and Inspections............................................................................................72
16. PUBLICATIONS ...................................................................................................73
17. REFERENCES.......................................................................................................74
18. APPENDICES ........................................................................................................76
Appendix A: Table of Abbreviations ......................................................................................76
Appendix B: Scalp Physician Global Assessmen t (ScPGA) ....................................................79
Appendix C: Modified Whole Body Itch Numeric Rating Scale (NRS) ..................................80
Appendix D: Scalp Itch Nume ric Rating S cale (NRS ).............................................................81
Appendix F: The Dermatology Li fe Quality Inde x (DLQ I)..................................................... 84
Appendix K: Treatment Sch ema for Dose Titration at Bas eline ..............................................94
Appendix L: Treatment Schema for Dose Titration at Week 16 .............................................. 95
Appendix M: Titration Blis ter Card Confi guration ..................................................................96
Appendix N: Active Treatment Blister Card Configuration .....................................................97
Appendix O: Placebo Treatment B lister Card Confi gurati on................................................... 98
CCICCI
CCI
&(/*(1(3523for Dose Tr Dose T35,(7$5DLQI)DLQI) ..........5<,1)250$7,2122
.......727
..............737
.........................
..........................
..........................
..........................
NRS)NRS) ..........
..................
ema for Doma for D
Blister CardBlister Card
e Treatmente Treatme
acebo Treaacebo Trea$5<
(7$5,(735,235
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 15 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879128] OF TABLES
Table 1: Study Objectives .....................................................................................................21
Table 2: Study Endpoints .....................................................................................................22
Table 3: Table of Events.......................................................................................................30
Table 4: Treatment Schema for Dose Titr ation at Visit 2 (Week 0)....................................... 45
Table 5: Treatment Schema for Dose Titr ation at Visit 7 (Week 16).....................................46
Table 6: Abbreviations and Specialist Terms ........................................................................76
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,214646
......7676
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 16 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879129] OF FIGURES
Figure 1: Study Design ..........................................................................................................25
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 17 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879130] common form of 
psoriasis, is typi[INVESTIGATOR_655053], demarcated erythematous plaques covered by a 
silvery scale ( Lebwohl, 2003a ).  The scalp is the most frequent area affected by [CONTACT_655079], 
occurring in up to 80% of patients ( van de Kerkhof, 1998 ).  These lesions can affect the hair-
bearing areas of the scalp, extending past the hair line, as well as in the retroauricular area and on 
the neck.  The lesions and associated flaking can be visible as well as highly pruritic, causing a 
negative impact on the patientâ€™s quality of life ( Kragballe, 2013; Szepi[INVESTIGATOR_110425], 2016 ). 
The presence of scalp hair makes application of topi[INVESTIGATOR_655054], limiting their effectiveness as well as compliance ( Warren, 2008; Feldman,
2003 ). Currently approved topi[INVESTIGATOR_655055].  In addition, potent topi[INVESTIGATOR_655056], skin atrophy, 
striae, telangiectasia, and hypothalamic-pi[INVESTIGATOR_221415]-adrenal (HPA) axis suppression ( van der 
Vleuten , 2001 ; Hogan, 1989 ).  Other topi[INVESTIGATOR_12491], such as coal tar and anthralin preparations 
have cosmetically unappealing formulations, foul odor, limited efficacy, and potential 
carcinogenic risk ( Chan, 2009 ).  Second-line therapi[INVESTIGATOR_655057], however, safety and efficacy d ata from c ontrolled clinical trials for 
these agents is limited ( Chan, 2009 ).  Efficacy data from controlled clinical trials involving 
treatment with biologics, such as ixekizumab has only recently been published ( Reich, 2016 ).  
Thus, there remains an unmet medical need in treating plaque psoriasis of the scalp, particularly 
in patients with moderate to severe plaque psoriasis of the scalp.
1.2. Compound Background 
Apremilast (CC-[ZIP_CODE]) is a specific phosphodiesterase type 4 (PDE4) inhibitor under development for use in the treatment of inflammat ory conditions.  PDE4 is one of the major 
phosphodiesterases expressed in leukocytes. PDE4 inhibition by [CONTACT_655086] (cAMP) levels in immune cells, which in turn down-regulates the 
inflammatory response by [CONTACT_394815]-inflammatory mediators such as tumor 
necrosing factor (TNF)- Î±, interleukin (IL)-23, IL-17, and other inflammatory cytokines, and 
increasing the production of anti-inflammatory mediators. 
In completed Phase [ADDRESS_879131] (OTEZLA
Â®) is approved in approximately forty countries worldwide for the treatment 
of adult patients with active psoriatic arthritis  and the treatment of patients with moderate to 
severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Apremilast remains under further clinical development for the treatment of inflammatory/ 
autoimmune disorders including BehÃ§etâ€™s disease, and ulcerative colitis. Further studies within the approved indications of plaque psorias is and psoriatic art hritis are also ongoing.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21on on 
ng a g a 
apyapydifficudifficuy
8;;FeldmanFeldman
ns may be ls may be
otent topi[INVESTIGATOR_655058], skylaxi
suppressiosuppressio
l tar and antar and a
efficacyeffica , an
as phototheas phototh
data fata fromromfffm
m m controllecontrolle
lylyrecently recentlyy
ating ating plaquaq
riasis of theasis of th
d
phosphodiphospho
ment of inflaent of inf
in leukocyn leukocy t
(cAMP) levcAMP) le
y reducingy reducin
)-)-Î±, Î±, intinerle
duction of auction of a
Phase [ADDRESS_879132] (OTEast (OTE
aduldult patit patil enen
severe plaqevere plaq
Apremprem
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 18 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Please refer to the Investigatorâ€™s Brochure (IB) for detailed information concerning the available 
pharmacology, toxicology , drug metabolism, clinical studies, and adverse event profile of the 
investigational product (IP).
1.3. Rationale
1.3.1. Study Rationale and Purpose
Plaque psoriasis of the scalp is often challenging to treat.  Scalp skin is also relatively 
inaccessible, making topi[INVESTIGATOR_655059] ( Ortonne, 2009 ).  
Given the visibility of the lesions and the scaling/ flaking as well as the itch associated with the 
disease, patients with plaque psoriasis of the scalp often experience considerable physical, 
psychological and social impacts to quality of life.
There remains an unmet medical need in treating p laque psoriasis of the scalp as currently 
approved topi[INVESTIGATOR_655060], poor treatment compliance, limited efficacy, and cosmetic appeal. As well, potent topi[INVESTIGATOR_655061], skin 
atrophy, striae, telangiectasia, and hypothalamic-pi[INVESTIGATOR_221415]-adrenal (HPA) axis suppression. Other 
topi[INVESTIGATOR_12491], such as coal tar and anthralin preparations, have the additional risk of carcinogenesis. Second-line therapi[INVESTIGATOR_655062], however safety and efficacy data from controlled clinical trials for most of 
these agents is limited.   Efficacy data from controlled clinical trials involving treatment with 
biologics, such as ixekizumab has only recently been published.
Apremilast (CC-[ZIP_CODE]) is a specific phosphodiesterase type 4 (PDE4) inhibitor approved for the 
treatment of both psoriasis and psoriatic arthriti s.  In Phase [ADDRESS_879133] 30 mg twice daily 
(BID) in the treatment of subjects with moderate to severe plaque psoriasis of the scalp.
1.3.2. Rationale for the Study Design
Exploratory analyses from the two pi[INVESTIGATOR_9205] [ADDRESS_879134] in subjects with 
moderate to severe plaque psoriasis (Study PSOR-008 and Study PSOR-009) demonstrated that 
apremilast 30 mg BID provided a treatment benefi t in the subset of subjects who also presented 
with plaque psoriasis of the scalp of moderate or greater severity at baseline using a six-point 
Scalp Physician Global Assessment (ScPGA).  The 6-point ScPGA scale ranged from 0 (clear), 
1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe).
This study will directly investigate the safe ty and efficacy of apremilast 30 mg BID, compared 
with placebo, in the treatment of subjects with mode rate to severe plaque psoriasis of the scalp.  
The primary endpoint will be the proportion of subjects who achieved ScPGA response at Week 16 (defined as ScPGA score of clear (0) or almost clear (1) with at least a 2-point 
reduction from baseline at Week 16), based on th e intent-to-treat (ITT ) population.  Based on 
Health Authority feedback, this study will us e a 5-point ScPGA scale ranging from 0 (clear), 
1 (almost clea r), 2 (mild), 3 (moderate), to 4 (severe), instead of the 6-point scale used in prior 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21009009)).  
hh the  the hh
cal, cal, 
s currents current ly 
ed by [CONTACT_655087]. As welal. As wel
h as tachyphas tachyp
HPA) PA) axis saxis 
e the addithe addit i
the scalp inthe scalp
m controllem contro
inical trialsinical tria
published.published.
sterase tyterase ty pepy
tis.  In Phas.  In Pha
with moith mo derde
rmrmed in theed in 
atment of matment 
assess the assess the
ects with mects with m
the Sthe S tudytu
s from the from the t
e plaque pse plaque ps
mmg BID g BID mm prop
psoripsori asis oasis o
ysician Glocian Glo
nimal), 2 (mnimal), 2 (m
his studyhis study wwyy
wiwithi plplhaceace
he prihe pr
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 19 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879135] in subjects 
with moderate to severe plaque psoriasis (Study PSOR-008 and Study PSOR-009) demonstrated improvement in itch severity using a Visual An alog Scale (VAS). In this study, improvement of 
itch will be assessed using Numeric Rating Scales (NRS) as these are considered to have better 
reliability and precision, and lesser potenti al for missing values, than the VAS ( Phan, 2012 ). The 
first secondary endpoint will be the proportion of subjects with â‰¥4-point reduction 
(improvement) from baseline in the Whole Body Itch NRS score at Week 16.  It is anticipated 
that approximately 80% of the subjects would be evaluable for this analysis, based on prior experience in Studies PSOR-008 and PSOR-009 as well as other clinical trials in moderate to 
severe plaque psoriasis ( Griffiths, 2015 ).
Eligible subjects will be randomized 2:[ADDRESS_879136] to baseline severity of scalp psoriasis.
1.3.3. Rationale for Dose, Schedule and Regimen Selection
Exploratory analyses from the two pi[INVESTIGATOR_9205] 3 studies (PSOR-008 and PSOR-009)
demonstrated that apremilast [ADDRESS_879137] in the selected patient population (Food and Drug 
Administration [ FDA] Guidance for Industry E10 ). 
 
 
 
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21inn
ubjects bjects 
onstrated onstrated
ovemovem ent ofent o
to have betto have be
(Phan, 2012Phan, [ADDRESS_879138] oent effec
placeboplacebo -conco
acyand safeand safey
nistratnistr ion [n [F
&((&&
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 20 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017 
 
 
 
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 21 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov [ZIP_CODE]. STUDY OBJECTIVES AND ENDPOINTS
Table 1: Study Objectives
Primary Objective
The primary objective of the study is to evaluate the clinical efficacy of apremilast 30 mg twice daily
(BID) compared with placebo, in subjects with mode rate to severe plaque psoriasis of the scalp, at 
Week 16.
Secondary Objective(s)
The secondary objectives are:
!To evaluate the safety and tolerability of apremilast 30 mg BID compared with placebo, in 
subjects with moderate to severe plaque psoriasis of the scalp.
!To evaluate the effect of apremilast 30 mg BID compared with placebo on itch over the whole
body caused by [CONTACT_655079]
!To evaluate the effect of apremilast 30 mg BID compared with placebo on itch associated with 
plaque psoriasis of the scalp
!To evaluate the onset of effect on itch over the whole body caused by [CONTACT_655088] 30 mg BID compared with placebo
!To evaluate the onset of effect on itch associated with plaque psoriasis of the scalp with 
apremilast 30 mg BID compared with placebo
!To evaluate the effect of apremilast 30 mg BID compared with placebo on health-related quality 
of life
Exploratory Objective(s)
The exploratory objectives are:
 
 
 
!To evaluate the effect of apremilast 30 mg BID compared to placebo on Dermatological Life 
Quality Index (DLQI)
 
 
CCIC
CI
CCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7bo, in o, in 
over the over the wh
on on itchitchasso
d by [CONTACT_109010] d by [CONTACT_655089] $7$7$7
([ADDRESS_879139] of apr
(DLQI)DLQI),(
(/35
523352
(1(*(1*(/*(/*
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 22 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 2: Study Endpoints
Endpoint Name [CONTACT_655121] (ScPGA)Proportion of subjects with ScPGA
score of clear (0) or almost clear (1)
with at least a 2-point reduction from baseline at Week 16. Week 16
Secondary Itch Numeric Rating 
Scale (NRS) [whole
body]Proportion of subjects with â‰¥4-point 
reduction (improvement) from 
baseline in the whole body itch NRS score Week 16
Itch NRS (Scalp) Proportion of subjects with â‰¥4-point 
reduction (improvement) from 
baseline in the scalp itch NRS score Week [ADDRESS_879140] on itch
NRS (whole body)Proportion of subjects with â‰¥4-point 
reduction (improvement) from 
baseline in the whole body itch NRS 
scoreBy [CONTACT_655090]-controlled 
Phase (Week 12, 
Week 8, Week 4, Week 2)
Onset of effect on itch
NRS (Scalp)Proportion of subjects with â‰¥4-point 
reduction (improvement) from 
baseline in the scalp itch NRS scoreBy [CONTACT_655090]-controlled 
Phase (Week 12, Week 8, Week 4, 
Week 2)
Dermatological Life Quality Index (DLQI)Change from baseline in DLQI total 
score Week 16
Exploratory   
ScPGA Proportion of subjects with ScPGA 
score of clear (0) or almost clear (1) 
with at least a 2-point reduction from 
baseline By [CONTACT_655091] (whole body) Proportion of subjects with â‰¥4-point 
reduction (improvement) from 
baseline in the whole body itch NRS 
scoreBy [CONTACT_655092] (Scalp) Proportion of subjects with â‰¥4-point 
reduction (improvement) from 
baseline in the scalp itch NRS scoreBy [CONTACT_655093]$7
[ZIP_CODE]$
nt t 
hhNRS NRS By [CONTACT_655094])21)
cts with cts with â‰¥4-4
ovement) frovement) fro
e scalp e scalp itchitch5<
ange from bange from b
corore e ,(
352352222
h NRS (whoNRS (who(
*(ItcIt*(*(*([ZIP_CODE]
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 23 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 2: Study Endpoints (Continued)
Endpoint Name [CONTACT_655122] 4, 8, 16 and 
32
 
  
 
 
  
  
 
    
 
Safety Type, frequency, 
severity, and 
relationship of adverse events to IPDay 0 through end of Observational 
Follow-UpStudy duration
CCICCI
CCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,217nd nd 77$7$7$7
)$
)))21)
<
7$
5,(
23
of adverse of advers
IPDD232323
(3230$
1)2,1
5<
(7$(7
35,235
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 24 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879141] (CC-[ZIP_CODE]) in subjects with moderate to severe plaque 
psoriasis of the scalp.
Approximately 300 subjects with moderate to seve re plaque psoriasis of the scalp will be 
randomized 2:[ADDRESS_879142] 16 weeks.  
Randomization will be stratified by [CONTACT_655095] (ScPGA) score 
(moderate [3], severe [4]) to ensure balance between treatment arms with respect to baseline severity of scalp psoriasis.
!Subjects randomized to the apremilast [ADDRESS_879143] 16 weeks
!Subjects randomized to the placebo treatment group will receive placebo tablets 
(identical in appearance to apremilast 30 mg tablets) orally twice daily for the first
16 weeks
!All subjects will receive apremilast [ADDRESS_879144] of four phases:
!Screening Phase â€“ up to 35 days
!Double-blind Placebo-controlled Phase â€“ Weeks 0 to 16
Subjects will receive treatment with one of the following:  
!apremilast 30 mg tablets orally BID or
!placebo tablets (identical in appearan ce to apremilast 30 mg tablets) orally BID
!Apremilast Extension Phase â€“ Weeks 16 to 32
!All subjects will be switched to (or continue with) apremilast 30 mg BID at 
Week 16. All subjects will maintain this dosing through Week 32.
!Observational Follow-up Phase
!Four-week Post-treatment Observational Follow-up Phase for all subjects who 
complete the study or discontinue from the study early.
After all subjects have completed the Week 16 Visit (or discontinued from the study), a Week 16 
database lock will be performed; the primary data analysis will be conducted  
.  However, unblinded data will only be made available 
to select Sponsor and Contract Research Orga nization (CRO) team member s involved with 
analysis of the data .  All other Sponsor, 
site, and CRO personnel directly involved with the conduct of the study, will remain blinded to treatment assignments until the final database lock at the conclusion of the study.  At the end of 
the study, after all sub jects have completed, or have been discontinued from the Apremilast 
CCICCI
CCI
CCIo selo sel(/*(1([ZIP_CODE],(7$5<,1)250$7,21 score score 
eline ne 
will receive will receive 
ive placebove plac
y twice dailytwice dail
rallyrally twitwyy ce 
nnPhase of Phase of
ase ase â€“â€“WeeWee
with one ofwith one o
s orally BIDs orally BI
nticalciln apn ap
ioionnPhase Phase 
ts will be swts will b
16. All sub16. All s
vational Fovational Fo
FourFour -wewe
comcomppmmm
all subjectsall subject
tabase lockbase lock
ectec
l&(CI
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 25 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Extension Phase (Weeks 16 to 32) and the Observational Follow-up Phase, the final analysis will 
be performed and a final Clinical Study Report will be generated.
Figure 1: Study Design
Abbreviation:  BID = twice daily.
The study will be conducted in compliance wi th the International Council for Harmonisation 
(ICH) of Technical Requirements for Registr ation of Pharmaceu ticals for Human Use/G ood 
Clinical Practice (GCP) and applicable regulatory requirements.
3.2. Study Duration for Subjects 
Subjects who complete the entire study will spe nd a total of approximately 41 weeks in this 
clinical trial:
!Up to 35 days (5 weeks) in the Screening Phase
!Weeks 0 to 16 (16 weeks) in the Double-blind Placebo-controlled Phase
!Weeks 16 to 32 (16 weeks) in the Apremilast Extension Phase
!Four-week (4 weeks) Post-treatment Observational Follow-up Phase
3.3. End of Trial
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol, 
whichever is the later date.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,212250250
ternationalternationa
of Pharmacof Pharma
ryyrequirequiy remrei
ects ects 
yywillwilly  spen spenll
eeks) in theeks) in the
(16 weeks)6 weeks)
o o 32 (32 (16 w6 w
week (4 weeeek (4 wee
End of TrEnd of Tr
d of Trial isd of Trial i
treatmreatm ent fnt 
quiquired fred iii or por pfff
whicheverwhichever
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 26 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879145] satisfy the following criteria to be enrolled in the study:
1. Males or females, â‰¥ 18 years of age at the time of signing the informed consent document
2. Understand and voluntarily sign an informed consent form (ICF) prior to any study-
related assessments/procedures being conducted. 
3. Be willing and able to adhere to the study visit schedule and other protocol requirements.
4. Have a diagnosis of moderate to severe plaque psoriasis of the scalp at screening and 
baseline as defined by:
a. ScPGA (See Appendix B ) score of â‰¥3 (moderate or severe) and,
b. Scalp Surface Area ( SSA) involvement of â‰¥20% and,
c. Inadequate response or intolerance to at least one topi[INVESTIGATOR_8588] (for example, 
potent or super potent topi[INVESTIGATOR_11930], vitamin D analogs, and combination 
products) for plaque psoriasis of the scalp.
5. Must be a candidate for phototherapy and/or systemic therapy for either body or scalp 
psoriasis lesions.  
6. Have moderate to severe plaque psorias is at screening and baseline as defined by:
a. Psoriasis Area and Severity Index (PASI) ( ) score â‰¥12 and,
b. Body Surface Area (BSA) â‰¥10% and,
c. Static Physician Global Assessment (sPGA) ( ) â‰¥3 (moderate)
7. Must be in good health (except for psoriasis) as judged by [CONTACT_737], based on 
medical history, physical examination, 12- lead electrocardiogram (ECG), clinical 
laboratories, and urinalysis
8. Must meet the following laboratory criteria
a. White blood cell count #3000/mm3(#3.0 x 109/L) and < 14,000/mm3(< 14 x 
109/L)
b. Platelet count #100,000/Î¼L (#100 x 109/L)
c. Serum creatinine âˆƒ1.5 mg/dL ( âˆƒ132.6 Î¼mol/L)
d. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase 
[SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic 
transaminase [SGPT]) âˆƒ2 x upper limit of normal (ULN)
e. Total bilirubin â‰¤ 2 mg/dL (34 Î¼mol/L)
f. Hemoglobin â‰¥ 9 g/dL (â‰¥ 5.6 mmol/L)
CCICCI
CCI
&(/*(1(ryry([ZIP_CODE],(7$5<,1)250$7,21ocumentcument
studystudy --
tocol requirtocol requi
alp at slp at s creencreen
r severesevere ) an) a
% and,% and,
ast one topi[INVESTIGATOR_655063], vitamroids, vitam
scalp.scalp.
d/or systemd/or system
psoripsori asis at asis at 
veriveritytyiii Inde Inyy
ea (ea (BSABSA )â‰¥)â‰¥
iananGlGlobal Aob
health (exchealth (e
, physical, physic
s, and urinas, and urina
meet the foleet the fo
a.a.WhiteWhite
101099
b.b.
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 27 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017g. Hemoglobin A1c âˆƒ9.0%
9. Females of childbearing potential (FCBP)â€ must have a negative pregnancy test at 
Screening and Baseline.  While on investigational product and for at least [ADDRESS_879146] use one of the approved contraceptive
Â§options described 
below: 
Option 1:  Any one of the following highly effective methods:  hormonal 
contraception (oral, injection, implant, transdermal patch, vaginal ring); 
intrauterine device (IUD); tubal ligation; or partnerâ€™s vasectomy;
OR
Option 2:  Male or f emale condom (latex condom or nonlatex condom NOT made 
out of natural [animal] membrane [for example, polyurethane]; PLUS one 
additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
4.3. Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Other than psoriasis, history of any clinically significant (as determined by [CONTACT_3786]) cardiac, endocrinologic, pulmonary, ne urologic, psychiatric, hepatic, renal, 
hematologic, immunologic disease, or other major uncontrolled disease.
2. Any condition, including the presence of laboratory a bnormalities, which would place the 
subject at unacceptable risk if he/she were to participate in the study.
3. Any condition that confounds the ab ility to interpret data from the study.
4. Pregnant or breast feeding5. Hepatitis B surface antigen positive at Screening
6. Anti-hepatitis C antibody positive at Screening
7. AST (SGOT) and/or ALT (SGPT) > 1.[ADDRESS_879147] andtotal bilirubin > ULN and/or 
albumin < lower limit of normal (LLN)
8. Active tuberculosis (TB) or a history of incompletely treated TB
                                                            
â€ A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the 
surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 
consecutive months).
Â§The female subjectâ€™s chosen form of contraception must be effective by [CONTACT_655096] (for example, hormonal contraception should be initiated at least 28 days before 
randomization).
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21omomNOT mNOT mm
PLUS one LUS on
) cervical c) cervical 
m m enrollmeenr
icant (as deant (as d
, neurolneurol ogio
major unconmajor uncon
laboratoryaboratory ay
were to partiwere to part
bilitbility y to into in
n positive an positive
odyodyposiposiyy titiiiivv
/or ALT (S/or ALT
er limit of nr limit of n
erculosis (Trculosis (T
                           
*(of childbearchildbea
l removal of  removal of
tmenopausamenopausa
consecutive monsecutive 
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 28 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879148] a posterior to 
anterior (PA) view (radiograph must be taken  within 12 weeks prior to screening or 
during the Screening Visit).  An addition al lateral view is strongly recommended but not 
required.
11. History of positive human immunodeficiency virus (HIV), or have congenital or acquired 
immunodeficiency (eg, common variable immunodeficiency disease)
12. Active substance abuse or a history of subs tance abuse within [ADDRESS_879149] 4 weeks prior to 
randomization.
14. Malignancy or history of malignancy, except for:
a. treated (ie, cured) basal cell or squamous cell in situ skin carcinomas; 
b. treated (ie, cured) cervical intraepi[INVESTIGATOR_28601] (CIN) or carcinoma in situ of 
the cervix with no evidence of recurrence within [ADDRESS_879150]â€™s life time prior to signing the 
informed consent and randomization, or major psychiatric illness requiring 
hospi[INVESTIGATOR_854] 3 years prior to signing the informed consent.
16. Psoriasis flare/rebound (defined as a sudden worsening of body plaque psoriasis or 
plaque psoriasis of the scalp which requires administration of prohibited medications) 
within [ADDRESS_879151] on psoriasis of the body and/or s calp during the course of the treatment phase of 
the trial:
a. Topi[INVESTIGATOR_8588], including medicated shampoos, coal tar and salicylic acid 
preparations, within 2 weeks prior to randomization (including but not limited to 
topi[INVESTIGATOR_11930], topi[INVESTIGATOR_198465] D analog preparations, tacrolimus, pi[INVESTIGATOR_031], or anthralin/dithranol).  
i. Exceptions:  
1. non-medicated shampoos for scalp lesions2. unmedicated emollients for body lesions
b. Conventional systemic therapy for psoriasis within 4 weeks prior to 
randomization (including but not limited to cyclosporine, corticosteroids, 
methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, 
sulfasalazine, azathioprine, or fumaric acid esters).
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ing ng 
significant ignificant 
oormrm.  Any.  Any
s prior to prior to
kin carcinoin carcino
iaia(CIN) (C or
hin 5 years hin 5 year
the subjectthe subjec
ajor psychiajor psychi
or to sir to si gningnin
sudden wosudden wo
h requires h requires 
informed conformed co
current use urrent use 
ththe bodye body ay
alal therapy,  therapyll
paratiparati ons, wons, 
topi[INVESTIGATOR_655064] c
tacrolimtacrolim
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 29 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017c. Intralesional corticosteroids on the scalp within 2 weeks prior to randomization
d. Phototherapy treatment of body or scalp psor iasis lesions within 4 weeks prior to 
randomization (ie, ultraviolet B (UVB), psoralen and ultravio let A radiation
[PUVA])
e. Biologic therapy:
i. TNF or IL-17 blockers such as adalimumab, brodalumab, certolizumab 
pegol, etanercept, infliximab, ixek izumab, secukinumab (or biosimilars for 
each) within 12 weeks prior to randomization
ii. Anti-IL-12 or anti-IL-23 monoclonal antibodies such as ustekinumab, 
guselkumab, or tildrakizumab, within 24 weeks prior to randomization
f. Use of any investigational drug beginning 4 weeks prior to randomization, or 5 
pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer)
18. Evidence of scalp and/or skin conditions that would interfere with clinical assessments19. Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources
20. Prior treatment with apremilast
21. History of allergy or hypersensitivity to any components of the IP
CCIor or 
mab, ab, 
mizationmization
mization, ormization, or
hever is lover is lo n
clinical asslinical ass
vioviolet (UVlet (UV
nts of the IPnts of the
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 30 CC-[ZIP_CODE]-SPSO-001 Amendment 1 Final: 30 Nov [ZIP_CODE]. TABLE OF EVENTS
Table 3: Table of Events
Screening Placebo-controlled Treatment Phase Apremilast Extension PhaseObservational 
Follow-up
Visit Number 1Baselinea
2 3 4 5 6 7 8 9 10/ETb11
Week -5 to 00
(Day 1)2
(Â± 4 days)4
(Â± 4 days)8
(Â± 4 days)12
(Â± 4 days)16
(Â±4 days)20
(Â± 4 days)24
(Â±4 days)32
(Â±4 days)[ADDRESS_879152] Dose
(Â± 2 weeks)c
Administrative/Demographics
Informed ConsentdX- - - - - - - - - -
Demographics X - - - - - - - - - -
Inclusion / Exclusion X X - - - - - - - - -
Medical and Disease History X - - - - - - - - - -
Prior / Concomitant Medications 
and Therapi[INVESTIGATOR_655065] X XXX X X X
Safety Assessment(s)
Height, BMI X - - - - - - - - - -
CXReX- - - - - - - - - -
Hepatitis B and C, TBfX- - - - - - - - - -
Hemoglobin A1C X - - - - - - - - - -
Weight X X - - X - X - X X X
Complete Physical Exam X - - - - - - - X -
Vital Signs X X X X X X X X X X X
Pregnancy Test for FCBP and 
Contraception EducationgXX - - - - - - - X -
12-lead ECG X - - - - - - - - - -
Clinical Laboratory EvaluationshXX - - - -X - - X -
CCI&(/*(priprietet(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
[ADDRESS_879153] Exten0$
[PHONE_13569]
days)days)202
(Â± (Â±44)222
12
,111
-<<<5<--5<5<5<5<--$555
75
--777$(7XX(7(7(75(7555, --35353535--233
523
523
--52525252--[ZIP_CODE]
--3(--((((XX1(((
((
XX(((1*(XX***/*nsnshhXX///*(/(/(/(/
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 31 CC-[ZIP_CODE]-SPSO-001 Amendment 1 Final: 30 Nov 2017Table 3: Table of Events (Continued)
Screening Placebo-controlled Treatment Phase Apremilast Extension PhaseObservational 
Follow-up
Visit Number 1Baselinea
2 34 5 6 78 9 1 0 / E Tb11
Week -5 to 00
(Day 1)2
(Â± 4 days)4
(Â± 4 days)8
(Â± 4 days)12
(Â± 4 days)16
(Â±4 days)20
(Â± 4 days)24
(Â±4 days)32
(Â±4 days)[ADDRESS_879154] Dose
(Â± 2 weeks)c
Vasculitis Assessmenti---- - --- - - -
Psychiatric Evaluationj---- - --- - - -
Adverse Events X X X X X X X X X X X
Psoriasis Flare Assessmentk---- - --- - - -
Clinical Efficacy Assessment(s)l
Whole Body Itch NRSm- XXX X X XX XX -
Scalp Itch NRSm- XXX X X XX XX -
ScPGA X X X X X X X X X X X
Patient Reported Outcomes
DLQI - X - X X - X - - X -
CCICCI
CCI
CCI
priprietet/*/**1(3X-(((3([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
nsion Phasesion Phase7,2222
990$0$0$0$
4 days)4 da2424
(Â±4Â±455025--)222
12
--111)1XX,1111
-<,5<5<5<5<XX$555
75
XX777$7XX777$(7
5235,(7
(35
/*(1(
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 32 CC-[ZIP_CODE]-SPSO-001 Amendment 1 Final: 30 Nov 2017Table 3: Table of Events (Continued)
Screening Placebo-controlled Treatment Phase Apremilast Extension PhaseObservational 
Follow-up
Visit Number 1Baselinea
2 34 5 6 78 9 1 0 / E Tb11
Week -5 to 00
(Day 1)2
(Â± 4 days)4
(Â± 4 days)8
(Â± 4 days)12
(Â± 4 days)16
(Â±4 days)20
(Â± 4 days)24
(Â±4 days)32
(Â±4 days)[ADDRESS_879155] Dose
(Â± 2 weeks)c
Optional Assessment(s) at Selected Investigative Sites
Photographso-X- - X -X- - X -
Dosing
Dispense IP - X - X X X X X X - -
Return and count IP tablets - - - X X X X X X X -
Abbreviations: BMI = body mass index; ; CXR = Chest Radiograph; DLQI = The Dermatology Life Quality Index; ECG = Electrocardiogram ; ET = 
Early Termination Visit; FCBP = females of childbearing potential;  
 IP = Investigational Product; NRS = Numeric Rating Scale; ; ScPGA = Scalp Physician Global 
Assessment;  TB = tuberculosis testing;  
aAll baseline assessments must be completed prior to randomization and dispensing of IP.
bVisit [ADDRESS_879156]-treatment Observat ional Follow-up Phase.
dWritten informed consent will be obtained by [CONTACT_079] [INVESTIGATOR_655066].
eCXRs taken within 12 weeks prior to screening will be accepted.  CXRs should be performed as indicated by [CONTACT_655097]/immunomodulatory therapy.  If such guidelines are not available/applicable, routine CXRs should be performed as per the Table of Events or when 
clinically indicated.
fThe QuantiFERONÂ®Gold test should be used for TB testing in lieu of the tuberculin skin test (TST) or purified protein derivative ([COMPANY_003]) test, if possible.
gFCBP:  Serum pregnancy tests will be performed at the Screening and Early Termination/Last Treatment Visit.  Urine dipstick pre gnancy test(s) will be performed at baseline, 
prior to dosing.  An unscheduled pregnancy test should be administered if the subject has missed a menstrual period.  The Inves tigator will educate all FCBP about the options 
for and correct use of contraceptive methods at the Screening and Baseline Visits and at any time when a FCBPâ€™s contraceptive mea sures or ability to become pregnant changes.
hRefer to Section 6.5, Procedures, for details regarding hematology, clinical chemistries, and urinalysis parameters to be tested.
iAt any time vasculitis is suspected.  See Section 6.5, Procedures
jAt any time when suicidal thoughts or a suicide attempt is identified.  See Section 6.5, Procedures
kAt any time, a psoriasis flare may be reported as an adverse event, provided it meets the protocol definition.  See Section 6.5, Procedures
lClinician assessments are to be performed after subject completes numeric rating scales and patient reported outcomes questionn aires as scheduled in the Table of Events.  
Clinician assessments must be done in the following order: ScPGA, .
mSubject assessment of whole body itch must be performed prior to scalp itch assessment.
nSubject assessments must be completed in the following order: whole body itch NRS, scalp itch NRS,  DLQI,  as scheduled in the T able of Events.
oPhotographs will be obtained from subjects who provide separate consent to be photographed and at select sites only.
CCICCI
CCI CCI
CCI CCI
CCI
CCI
CCI CCICCI
&(/priprietet/*(1([ZIP_CODE],(7$= tuberculosi= tuberculosi
f IP.f IP.
y discontinuesy discontinues
ed to enter the d to enter the
esignee prior esignee prio
should be perfshould be
re not availabnot availab
ieeu of theu of the tubetub
ning and Earlyning and E
administered dministered 
ening and Basening and B
ng hematologyg hematol
.55, Procedure, Procedure
de attempt is ide attempt is id
ed as an adveed as an adv
ed after subjeced after subje
n the followinthe followin
itch must be pmust be
mpleted in thempleted in th$5<,1)250$7,21e Corporae Corpora
21
nsion Phasesion Phase7,2222
990$0$0$0$
4 days)4 da2424
(Â±4Â±455025)222
--111)1,111
X<,5<XXXX5<5<5<$55<55I= The Derm= The De
d fromd from subjectsubject7$5(7$
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 33 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov [ZIP_CODE]. PROCEDURES
The following administrative/demographic procedures will be conducted as outlined in the Table 
of Events, Table 3 .
Informed Consent
An informed consent form (ICF) must be signed by [CONTACT_12140]-related 
assessments are performed.  Details of the informed consent process may be found in 
Section 13.3.
Inclusion/Exclusion Criteria
Subjects must meet all inclusion criteria (Section 4.2) and must not have any of the conditions 
specified in the exclusion criteria (Section 4.3) to qualify for participation in the study.  The 
subjectâ€™s source documents must support his/her qualifications for the study (eg, if a female subject does not require pregnancy testing and birth control because of a hysterectomy, the date 
of the hysterectomy must be included in the medical history).
Medical and Disease History
Relevant medical history, as defined in the electronic Case Report Form (eCRF) Completion 
Guidelines and the Study Manual, should be r ecorded, including smoking and alcohol history, as 
well as previous relevant surgeries (please refer to the eCRF Completion Guidelines and the Study Manual for further details).  Disease history includes history of psoriasis and psoriatic 
arthritis.
Prior/Concomitant Medications and Therapi[INVESTIGATOR_655067]/used by [CONTACT_655098] d.  Other key medications and therapi[INVESTIGATOR_014], such as previous 
treatment for tuberculosis (TB) or relevant dis eases, should be recorded.  Please refer to the 
eCRF Completion Guidelines and the Study Ma nual for additional instructions and for further 
details.
All medications and therapi[INVESTIGATOR_109006], including topi[INVESTIGATOR_8593] (used within the last 5 years prior 
to randomization), systemics, and all medications and therapi[INVESTIGATOR_477037], should be 
recorded.  The stop dates for all medications and therapi[INVESTIGATOR_477038].  Responses to prior psoriasis therapi[INVESTIGATOR_76323].  Please refer to the eCRF Completion Guidelines and the St udy Manual for additional instructions.
6.1. Screening Period
Screening evaluations will be performed for all subjects to determine study eligibility. These 
evaluations must be completed within [ADDRESS_879157] eligibility, but exclusionary results may be 
re-tested one time within the screening wi ndow, without Celgene Medical Monitor approval.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21condicondi titiiiono
e study.  Th study.  Th
(eg, if a fem(eg, if a fem
hysterectomhysterectom
port Form (port For
uding smokding smok
CRF CoRF Co mpml
ludes histoludes histo
pi[INVESTIGATOR_655068]
d.  Other kd.  Other 
evant diseaevant di
the Studythe Stud
ies for psores for pso
mics, and amics, and
dates for allates for a
ses to priores to prior
oon Guidelin Guid
ScreeniScreeni
ening evaluening eval
aluatuatioions mns m
Waivers Waivers 
cum
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 34 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879158] complete these assessments in the following order: 1) ScPGA;  
The following assessments will be performed at screening as specified in the Table of Events, 
Table 3 , after informed consent has been obtained:
!Demographics (initials, date of birth, sex, race, and ethnicity-if allowed by [CONTACT_13125])
!Prior disease therapi[INVESTIGATOR_014]: includes topi[INVESTIGATOR_2855], systemic, and phototherapi[INVESTIGATOR_014]
!Complete medical history (all  relevant medical c onditions d iagnosed/ occurring prior 
to screening should also be included)
!Height
!Weight
!Complete physical examination
!Vital signs (including blood pressure, temperature, and heart rate)
!Chest radiograph (historic scans within 12 weeks of screening are allowed)
!12-lead electrocardiogram (ECG)
!Scalp Physician Global Assessment
 
!Hematology panel 
!Chemistry panel (including Hemoglobin A1C)
!Urinalysis
!Hepatitis B and C screening
!TB testing
!Serum pregnancy test is required for all female subjects of childbearing potential.  
Counseling about pregnancy precautions and the potential risks of fetal exposure 
!Adverse event assessment (begins when the subject signs the informed consent form)
6.2. Treatment Period
The subject will begin treatment upon confirmation of eligibility. For visits within the Placebo-
controlled Phase and Apremilast Extension Phase,  an administrative window of Â± 4 days is 
CCICCI
C
CI
&(/*(1(35anelel
panel panel (i(incl
ysisysis
epatiepati titiiis B as B a
TB testinTB test
!SeruSer
CC5235,(7$5<,1)250$7,21occurring occurring
e, and heare, and hea
eeks of screeks of sc
235
352
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 35 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017permitted.  For visits within the Observational Follow-up Phase, an administrative window of Â± [ADDRESS_879159] should complete the 
questionnaires in the following order when a pplicable: 1) whole body itch NRS, 2) scalp itch
NRS,  4) DLQI,  
During the treatment period, efficacy assessments may be performed by [CONTACT_477060] a study visit, but only after the subject has completed the 
NRS and health-related quality of life (HRQoL) assessments, when required.  The investigator performing efficacy assessments shall make independent observations at a given study visit and 
shall not review previous assessments or subject-derived data in advance of conducting the 
assessments.  When conducting the efficacy assessments, the investigator must complete these assessments in the following order: 1) ScPGA; . 
The following evaluations/assessments will be performed at the frequency specified in the Table 
of Events, Table 3 .
!Patient reported outcomes or health-related quality of life (HRQoL)
!Concomitant medications evaluation
!Concomitant procedures evaluation
!Vital signs
!12-lead electrocardiogram (ECG)
!Weight 
!!Hematology panel 
!Chemistry panel 
!Urinalysis
!Adverse event evaluation (continuously)
!Efficacy assessments (see Section 6.4)
!Urine pregnancy test (prior to dosing on Day 1)
!IP dispense and return
!Photography (select site s and involving subjects signing a separate photography ICF)
6.2.1. End of Treatment
An end of treatment (EOT) evaluation will be performed for subjects who are withdrawn from 
treatment for any reason as soon as possible af ter the decision to permanently discontinue 
treatment has been made. The end of treatment (Visit 10) assessments will also be performed for 
subjects who complete the study.
CCICCI CCI
CCI
CCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d the d the 
stigator stigator 
dydyvisivisiyy t andt andiii
ctcting the ing the 
complete tcomplete
. 
cy specifiey speci
f lifefe(HRQRQ
vent evaluaent eval
cycyassessmassessm
rine pregnarine pregna
&IP IP ddispeisp
!PhoPho
[IP_ADDRESS].2
ne n)2
235
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 36 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879160] complete 
the questionnaires in the following order: 1) body itch NRS, 2) scalp itch NRS, 3) DLQI,  
.
During the end of treatment visit, efficacy assessments may be performed by [CONTACT_477060] a study visit, but only after the subject has completed the 
NRS and HRQoL assessments, when required.  The investigator performing efficacy assessments shall make independent observations at a given study visit and shall not review 
previous assessments or subject-derived data in advance of conducting the assessments.  When 
conducting the efficacy assessments, the investigator must complete these assessments in the following order: 1) ScPGA, .
The following evaluations will be performed as specified in the Table of Events, Table 3 :
!Patient reported outcomes or health-related quality of life (HRQoL)
!Concomitant medications evaluation
!Concomitant procedures evaluation
!Complete physical exam
!Vital signs
!Weight 
!Hematology panel 
!Chemistry panel 
!Urinalysis
!Adverse event evaluation (continuously)
!Efficacy assessments (see Section 6.4)
!Serum pregnancy test 
!IP return
!Photography (select sites and involving subjects signing a separate photography ICF)
6.3. Follow-up Period 
All subjects should be followed for [ADDRESS_879161] complete these assessments in the following order: 1) ScPGA,
CCIC
CI
CCI
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21hen en 
n the the
Tableable 33::
L))
continuouslntinuous
see Section  Section
est est 
hyhy(select s(selecyy
owow-up Peup P
shoulshoul ddbe be 
ade known known
described described 
uring the fouring the f
qualified qualified 
ssessmssessm
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 37 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017The following evaluations will be performed at the Observational Follow-up Visit as specified in 
the Table of Events, Table 3.
!Concomitant medications evaluation
!Concomitant procedures evaluation
!Weight
!Vital signs
!Adverse event evaluation 
!Efficacy assessments (ScPGA, )
6.4. Efficacy Assessments
The following assessments will be conducted as outlined in the Table of Events, Table 3 :
!Numeric Rating Scale Assessments
Whole Body Itch Numeric Rating Scale Assessment
Prior to any other procedures or a ssessments being performed during the treatment 
period, the subject w ill be asked to assess whole body itch and select a number on a 
scale of 0-10, where â€œ0â€ represents no itch, and â€œ10â€ represents the worst imaginable 
itch.  The number selected by [CONTACT_655099].  SeeAppendix C .
The Whole Body Itch NRS scale has been validated among patients with moderate to 
severe plaque psoriasis, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity 
(Kimball, 2016 ).
Scalp Itch Numeric Rating Scale Assessment
After completing the Whole Body Itch NRS, the subject will be asked to assess scalp 
itch and select a number on a scale of 0-10, where â€œ0â€ represents no itch, and â€œ10â€ 
represents the worst imaginable itch.  The number selected by [CONTACT_655099].  See Appendix D .
The Scalp Itch NRS was derived from the Whole Body Itch NRS.  
 
!Scalp Physician Global Assessment 
The ScPGA is a measurement of overall scalp involvement by [CONTACT_655100].  The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: 
erythema, scaling and plaque elevation.  When making the assessment of overall 
scalp severity, the Investigator should factor in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the 
severity of each sign is averaged across all areas of involvement, including cleared 
lesions.  
CCICCI
CCI
&(/*(1Scalp PhScalp Ph
The The1([ZIP_CODE],(7$5<,1)250$7,21nts, ts, TableTable 33
rformoredddudu
ody itch andody itch 
â€œ10â€ repre10â€ repr
l be recordebe recor
been validaeen valid
int change int change 
icallycally mmyyeanean
ting Scale Aing Scale
WhoWho le Bole Bo
umber on aumber on a
worst imagiorst imag
hhe database databa
lp Itch NRlp Itch NR
timti(1(*(1
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 38 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017In the event of different severities across signs of psoriasis, the sign that is the 
predominant feature of psoriasis should be used to help determine the ScPGA score.
See Appendix B for grading criteria.
!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$
250)21)2,1)<5<$5<$57$(7$5,(75,(35,
[ZIP_CODE](31(3(1(*(1/*((/*(/*(/
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 39 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017 
 
 
 
 
  
6.5. Safety Assessments
!Contraception Education
The risks to a fetus or to a nursing child from apremilast are not known at this time.  
Results of animal and in vitro studies can be found in the IB.
All females of childbearing potential (FCBP) must use one of the approved 
contraceptive options as described in Section 4.2while on IP and for at least [ADDRESS_879162]â€™s chosen form of 
contraception must be effective by [CONTACT_81662] (for example, hormonal contraception should be initiated at least 28 days before 
randomization).
At screening and at baseline, and at any time during the study when a female subject 
of childbearing potentialâ€™s contraceptive measures or ability to become pregnant 
changes, the Investigator will educate the subject regarding contraception options and 
correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.
!Serum and Urine Pregnancy Tests for Females of Childbearing Potential 
(FCBP)
A serum pregnancy test with a sensitivity of â‰¤ 25 mIU/mL will be required for FCBP 
subjects at screening and at the Early Termination or Last Treatment Visit.  In 
addition, a local urine pregnancy test kit will be provided by [CONTACT_655101], prior to 
dosing.  An unscheduled pregnancy test s hould be performed if the FCBP subject has 
missed a menstrual period.
!Chest Radiograph (CXR)
A CXR is required during Screening.  A PA v iew is required; an additional lateral 
view is strongly recommended but not required.  Alternatively, PA or PA/lateral 
radiographs that were taken within the [ADDRESS_879163] radiographs should be perfor med as indicated by [CONTACT_655102]/immunomodulatory therapy.  If 
such guidelines are not available/applicable, routine CXRs should be performed when clinically indicated.
!Hepatitis B and C
Hepatitis testing will include hepatitis B su rface antigen and anti-hepatitis C antibody.
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21atat thi this times time
e approved approved
and for at lend for at l
ubjectâ€™s chubjectâ€™s c
ubject is ranubject is ra
e initniiated aed
during the suring the s
easures or aeasures or a
e subject ree subject r
e contraceptcontracep
y Tests for Tests for 
t with a senwith a sen
g and at theand at the
urine pregnurine pregn
rformed at rformed at 
uunschedulnschedu
menstrual menstrual
st Radiogrst Radiogr
A CXR A CXR is is 
view is sview is
radidio
ChCh
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 40 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017!TB Testing
The QuantiFERONÂ®-TB Gold test should be used in lieu of the tuberculin skin test 
(TST) or purified protein derivative ([COMPANY_003]) skin test if possible.  This test result must 
be negative within one month prior to first administration of IP or prior completed 
treatment was documented.  
!Vital Signs, Height, and Weight
Vital signs, including temperature, pulse, and seated blood pressure, will be taken 
during the visits indicated in Table 3. Height will be measured and recorded at 
Screening; weight will also be measured and recorded at screening and then as 
indicated in Table 3 . Body mass index (BMI) will be calculated at Screening.
!Complete Physical Examination
A complete physical examination includes evaluations of skin, nasal cavities, eyes, 
ears, lymph nodes, and respi[INVESTIGATOR_696], cardiovascular, gastrointestinal, neurological, and 
musculoskeletal systems.  The complete physical examination is done at screening 
and at the Early Termination or Last Treatment Visit (Visit 10).
!Vasculitis Assessment
The PDE4 inhibitors, including apremilast, have been shown to produce 
inflammatory perivascular histopathological changes in animal studies (eg, rodent 
toxicology studies).  The Investigator should be watchful for any signs and symptoms of vasculitis at all times.  Any suspi[INVESTIGATOR_655069], doing a physical examination, reviewing adverse 
events, and performing diagnostic procedures, as clinically indicated.  A subject with signs and symptoms of possible vasculitis should receive a thorough evaluation as 
described above, be managed as medically appropriate, and continued with follow-up 
until the signs and symptoms of vasculitis have resolved.
!Psychiatric Evaluation
Apremilast prescriber information (eg, Summary of Product Characteristics, Package 
insert) includes a warning regarding depression and suicidal thoughts. Patients with 
chronic diseases may be prone to depression. The risks and benefits of starting or continuing treatment with apremilast should be carefully assessed if patients report 
previous or existing psychiatric symptoms or if concomitant treatment with other 
medicinal products likely to cause  psychiatric events is intended. At any time during 
the study (post-randomization), subjects who have suicidal thoughts or behavior 
should be evaluated. If the psychiatrist deems the subject not to be a risk for suicide, 
the subject may remain in the study, but if a risk of suicide is confirmed, the subject 
must be discontinued from the study. If the subject is discontinued, the subject 
should return for the Observational Follow-up Visit.
A copy of the psychiatric evaluation report must be in the subjectâ€™s source 
documentation, especially if the subject is confirmed not to be at risk for suicide and 
is continuing in the study.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ng.ng.
al cavital cavit ies,ies
nal, neurolnal, neurol
nis done ais don
it 10).t 10).
been shownbeen show
hanges in ahanges in a
d be watchd be watch
of vasculitof vasculi
ing a physing a physi
proceduresprocedures
vasvasculiculititiiiss
d as medicad as medi
oms of vascms of v
onon
riber informriber inform
s a warnings a warning
eases mayeases may byy
ng treatmeng treatmen
ous or existous or exist
edicinal prodicinal pr
thhe studye study (p(yy
shoulshoul d bd 
thhe sue 
mm
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 41 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017!Twelve-lead Electrocardiogram
A 12-lead ECG will be performed after the subject has been supi[INVESTIGATOR_17044] 
3 minutes.  ECGs will be performed at screening as indicated in Table 3.   ECGs will 
be evaluated by a central reader.
!Clinical Laboratory Evaluations
Clinical laboratory evaluations will be performed by a central laboratory and as 
indicated in Table 3. Clinical laboratory evaluations include complete blood count 
(red blood cell [RBC] count, hemoglobin, hematocrit, white blood cell [WBC] count and differential, absolute WBC counts, platelet count); serum chemistries (total 
protein, albumin, calcium, phosphorous, glucose, total cholesterol [TC], triglycerides, 
high-density lipoprotein [HDL], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C ], adiponectin, uric acid, total bilirubin, 
alkaline phosphatase, aspartate aminotransferase [AST; serum glutamic-oxaloacetic 
transaminase, SGOT], alanine aminotransferase [ALT; serum glutamic pyruvic transaminase, SGPT], sodium, potassium, chloride, bicarbonate [carbon dioxide, 
CO
2], blood urea nitrogen, creatinine, lactate dehydrogenase [LDH], and 
magnesium); as well as Hemoglobin A1C at the Screening Visit, and dipstick urinalysis (specific gravity, pH, glucose,  ketones, protein, blood, bilirubin, leukocyte 
esterase, nitrite, and urobilinogen).  Dipstick urinalysis will be performed by [CONTACT_19979]; microscopic urinalysis (epi[INVESTIGATOR_1663], RBC, WBC, and casts) will be performed only if the dipstick urinalysis is abnormal.
Fasting is not required.  However, if significant elevation of serum lipid(s) is 
observed, a fasting re-test should be requested to determine whether or not elevation was caused by [CONTACT_188103].  
!Psoriasis Flare Assessments
Psoriasis flare represents an atypi [INVESTIGATOR_477040] ( Carey, 2006 ).  It is defined as a sudden intensification of psoriasis 
requiring medical intervention or a diagnosis of new generalized erythrodermic, 
inflammatory, or pustular psoriasis.  A m ore typi[INVESTIGATOR_2855], gradual worsening of plaque 
psoriasis would not be recorded as an adverse event (AE). 
!Adverse Events
Details of AE reporting may be found in Section 10.1.
 
 
 
 
 
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21oununt tnn
al l 
glycerides,glycerides
DLDL--C]C], l, lowow
bilirubin, bilirubin, 
tamictam -oxaloxal
glutamic pyutamic py
nate [carbonnate [carb
ase [LDH]se [LDH]
ning Visit, ng Visit, 
rotein, bloootein, 
nalysis willalysis will
ithelialhelial  cell cellll
alysis lysis is is abnabn
gnificant elgnificant 
 requested requested
ss
s an atyan aty pi[INVESTIGATOR_655070]
0606).  It is de).  It is d
interventintervent ioio
or pustulpustul ar par
ululd not be rd not be
EventsEvents
ils oils of fAE rAE r
/*((/(/*(/
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 42 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879164] after the who le body itch NRS and 
scalp itch NRS efficacy assessments and in the order that they are described below 
and as indicated in Table 3 .
!
 
 
!Dermatology Life Quality Index (DLQI)
During the treatment phase (see Table 3 ), DLQI ( Finlay, 1994 ) will be assessed by 
[CONTACT_655103], after completing the Whole Body Itch NRS, S calp 
Itch NRS,  and prior to any other procedures or assessments 
being performed.  The DLQI was developed as a simple, compact, and practical 
questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease ( Finlay, 1994 ).  The instrument contains [ADDRESS_879165]â€™s skin.  With the exception of Item Number 7, the subject responds 
on a four-point scale, ranging from â€œVery Muchâ€ to â€œNot at All.â€  Item Number [ADDRESS_879166]â€™s skin prevented 
them from working or studying (Yes or No), and if â€œNo,â€ then the subject is asked 
how much of a problem the skin has been at work or study over the past week, with response alternatives being â€œA lot,â€ â€œA little,â€ or â€œNot at all.â€  
The DLQI Total score has a possible range from [ADDRESS_879167] that the DLQI can be grouped into six subscales: symptoms and 
feelings; daily activities; leisure; work/school; personal relationships; and treatment.  
Scores for four of the subscales (symptoms and feelings, daily activities, leisure, and personal relationships) range from 0 to 6; scores for two of the subscales 
(work/school and treatment) range from 0 to 3.  Higher scores correspond to poorer 
health-r elated qu ality of life.  See Appendix F .
 
 
 
CCICCI
CCI
CCI
C
CI&(/*(1([ZIP_CODE],(7$5<,1((Finlay, 199Finlay, 19
leteting the Wing the W
rior torior to any oany
oped as a sioped as a s
y clinical sclinical s
19941994 ).  Th).  Th
he exceptionexceptio
g frog fro m mâ€œVâ€œVe
art of whicart of w
studying (Ystudying (Y
blem the skiem the ski
ives being ives bein
otal score hotal score
thth--relrelated ated
pers suggesers sugges
ings; dailyings; daily1)250$7,21NRS and RS and 
d below d below 
cores for focores for f
personal personal 
(workwork
heahea)21)2,1)
&(C
C
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 43 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017 
6.8. Photography
Photographic assessments will be done at selected sites to provide supportive 
evidence of efficacy as scheduled in Table 3 .  The procedure for taking the 
photographs and processing and shippi[INVESTIGATOR_655071] a separate 
procedure manual distributed to investigational sites performing photographic assessments.
Photographic assessments are an optional part of this study.  Subjects enrolled at the 
selected photography sites will be asked to  provide separate consent prior to being 
photographed. 
CCIC
CI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21parate parate 
ic 
enrolled aenrolled a
nt prior to bnt prior to 
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 44 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879168](s)
The chemical name [CONTACT_477096] (CC-[ZIP_CODE]) is acetamide, N-[2-[(1S)-1-(3-ethoxy-4-
methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl].
Apremilast will be supplied by [CONTACT_1034], Celgene Corporation, and labeled appropriately as 
investigational product for this study.  
All IP will be provided in blister cards throughout the entire study.  Apremilast will be provided 
as 10, 20, or [ADDRESS_879169] (IP), will be taken orally twice daily, approximately [ADDRESS_879170] ion of food or drink.  To mitigate potential 
gastrointestinal (GI) side effects, dose titration will be implemented in the first week of this study 
(see Table 4 ).
During Week 0 (Days 1-7), subjects will be dispensed dose titration blister cards with 10, 20, and 
[ADDRESS_879171] 7 days containing the titration supplies or matching placebo (see Table 4 Treatment Schema for Dose Titration at Visit 2 [Week 0] which 
details the titration supplies from Day 1 to Day 7).
At Visit 2 (Week 0), subjects who meet entry criteria will be randomized using a permuted block 
randomization in  parallel 2:[ADDRESS_879172] 30 mg BID or placebo, using a 
centralized Interactive Response Technology (IRT).   IP will be dispensed as indicated below.
!Weeks 0 to 16: Double-blind, Placebo-controlled Treatment Phase: Apremilast 30 mg 
BID or placebo BID. 
âˆ€Week 0 to 1: subjects will be dose titrated as described above and detailed in
Table 4 .
!Weeks 16 to 32: Apremilast Extension Phase: Apremilast 30 mg BID. 
âˆ€Week 16 to 17: subjects will be dose titrated as described below and detailed 
inTable [ADDRESS_879173]; dummy titration blister cards (dosing at 30 mg BID directly) will be used for subjects 
initially randomized to receive apremilast [ADDRESS_879174] 30 mg tablets which are to be taken twice 
daily.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ided ded 
[ADDRESS_879175] Ex
to 17: subjto 17: su
e5.
all subjectsall subjec
ized to placzed to plac
titration btitration b
dummy dummy tititratrii
andomized domized
ioonnPhase, hase, 
yy..
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 45 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017The treatment schema for dose titrati on at baseline is shown in Table 4.
Table 4: Treatment Schema for Dose Titration at Visit 2 (Week 0)
Week [ADDRESS_879176] 
30 mg BID10mg A
20mg P 
30mg P10mg P
20mg P 
30mg P10mg A
20mg P 
30mg P10mg A
20mg P 
30mg P10mg A
20mg P 
30mg P10mg P
20mg A 
30mg P20mg A 
30mg P20mg A 
30mg P20mg A 
30mg P20mg P 
30mg A20mg P 
30mg A20mg P 
30mg A
Placebo 10mg P
20mg P 
30mg P10mg P
20mg P 
30mg P10mg P
20mg P 
30mg P10mg P
20mg P 
30mg P10mg P
20mg P 
30mg P10mg P
20mg P 
30mg P20mg P 
30mg P20mg P 
30mg P20mg P 
30mg P20mg P 
30mg P20mg P 
30mg P20mg P 
30mg P
A=Apremilast; BID= twice daily; P= Placebo.
During Weeks 16 to 32, the IP will remain blinded, to prevent study personnel and subjects from knowing the IP assignment in th e 
Placebo-controlled Treatment Phase and to maintain the blind regarding the initial treatment assignment, all subjects will rece ive dose 
titration cards at Visit 7 (Week 16).  Alt hough only subjects initially randomized to place bo will be dose titrated during their first 
week of the Apremilast Extension Phase, all subjects entering the Apremilast Extension Phase will receive identically-appearing 
titration/treatment cards as shown in Table 5 .
CCIpriprietet,(7$5<,1)250$7,21e Corporae Corpora
21
$7
Day 5Day 50
MM P55525
A
mg Pg P20mg A20mg
30m30m222
12
mg PP20mg P20mg
30m30m,111
$55<551
ersonnel anersonnel a
rding the inrding the in
allyallyrandomrandomyy
g the the ApremAprem
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 46 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 5: Treatment Schema for Dose Titration at Visit 7 (Week 16)
Week [ADDRESS_879177] 
30 mg BID10mg P
20mg P 
30mg A10mg P
20mg P 
30mg A10mg P
20mg P 
30mg A10mg P
20mg P 
30mg A10mg P
20mg P 
30mg A10mg P
20mg P 
30mg A20mg P 
30mg A20mg P 
30mg A20mg P 
30mg A20mg P 
30mg A20mg P 
30mg A20mg P 
30mg A
Placebo to 
APR 30 
BID10mg A
20mg P 
30mg P10mg P
20mg P 
30mg P10mg A
20mg P 
30mg P10mg A
20mg P 
30mg P10mg A
20mg P 
30mg P10mg P
20mg A 
30mg P20mg A 
30mg P20mg A 
30mg P20mg A 
30mg P20mg P 
30mg A20mg P 
30mg A20mg P 
30mg A
A=Apremilast; BID= twice daily; P= Placebo.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietet7,2
50$$$$
PMPM05
20mg P 20mg P 
30mg A30m555
125
20mg A0mg A
30mg P30m111)
5<5<5<5<1
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 47 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879178] will be taken orally twice daily, approximately 12 hours apart, without 
restriction of food or drink.  To mitigate potential gastrointestinal (GI) side effects, dose titration 
will be implemented in this study.  During Week 1 (Days 1-7) and Week 16 (when placebo 
subjects are switched to receive apremilast 30 mg BID), subjects will be dispensed blister cards 
with 10, 20, and [ADDRESS_879179](s) only.  Therefore, for a drug to be subject to the overdose definition it must be both 
required and an investigational drug.  In this study the only required and investigational drug is 
apremilast and the control arm drug (ie, placebo), he nce overdose definition will apply to only 
apremilast (or matching pl acebo).  Other required or optional non-IP intended for prophylaxis of 
certain side effects, etc, are excluded from this definition.
Overdose for this protocol, on a per dose basis, is defined as ingestion of [ADDRESS_879180] (or matching placebo) tablets in any 24-hour period whether by [CONTACT_285917]. On a schedule or frequency basis, an overdose is defined as dosing more than 4 
times during any 24-hour peri od. 
7.4. Method of Treatment Assignment
At Visit 2 (Week 0), subjects who meet entry criteria will be randomized using a permuted block 
randomization in  parallel 2:[ADDRESS_879181] 30 mg BID or placebo, using a 
centralized Interactive Response Technology (IRT).  Designated research personnel at the 
investigational sites will be assigned passw ord protected, coded identification numbers, which 
gives them authorization to enter the IRT to randomize subjects.  
The system will present a menu of questions by [CONTACT_655104]. When all questions have been answered and the subject 
deemed eligible, the IRT will assign a randomization identification number.  
Confirmation of the randomization will be sent to the investigational site, Celgene, and/or its 
representative. The confirmation reports should be maintained as source documents. During the 
study visits, the pharmacy or authorized study pers onnel at the investigational site will dispense 
coded IP kits in accordance with the rando mization number assigned by [CONTACT_6606].
7.5. Packaging and Labeling
The label(s) for IP may include, but may not be limited to, Sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of IP per container, lot number, expi[INVESTIGATOR_5695] (w here applicable), medication identification/kit 
number, dosing instructions, storage conditions, and required caution statements and/or 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ions ions 
the investthe invest igi
ioon nitit mmustustmmm
nd investid investi ga
finitnitioion wilnw i
IPPi[INVESTIGATOR_655072] i
ignmentgnment
entryentry  cricriytetii
ve eitve eit her apher
TechnoTechn loogyg
igned passwgned passw
enter the IRenter the 
a menu oa menu o f
rm eligibilim eligibi
he IRT willhe IRT wil
of f ththe rande ran
ive. The cove. The co
sits, the phthe phi
d IP kid IP ki ts in  ini
&[IP_ADDRESS].
he lhl
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 48 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879182] Accountability and Disposal 
The Investigator(s) or designee(s) is responsible for accounting for all IP that is issued to and returned by [CONTACT_137825].
The Investigator(s) or designee(s) is responsible for taking an inventory of each shipment of IP 
received, and comparing it with the accompanying IP accountability form.  The Investigator(s) or 
Pharmacist(s) will verify the accuracy of the information on the form, sign and date it, retain a copy in the study file, and return a copy to Celgene.
At the study site, all IP will be stored in a locked, safe area to prevent unauthorized access.
The IP should be stored as directed on the package label.Celgene (or designee) will review with the Inve stigator and relevant site personnel the process 
for IP return, disposal, and/or destruction including responsibilities for the site versus Celgene 
(or designee). 
7.6.1. Record of Administration
Accurate recording of all IP administration (including dispensing and dosing) will be made in the 
appropriate section of the subjectâ€™s eCRF and source documents.
7.7. Investigational Product Compliance
Study personnel will review the instructions printed on the package with the study subjects prior to dispensing the IP.  Investigational product will be dispensed as noted in the Table of Events,Table 3.   The subjects will be instructed to return the IP containers, including any unused 
medication, to the study site at each visit for tablet counts and reconciliation.  Subjects will be 
asked whether they have taken their IP as inst ructed at each study visit.  Any problems with IP 
compliance will be reviewed with the subject.  If a subject misses [ADDRESS_879183] should be terminated from the Treatment Phase of the study, and enter into the Observational Follow-up Phase.
Gross compliance problems (eg, missing 4 or more consecutive days of dosing or taking less 
than 75% of the doses between study visits) are prot ocol deviations and should be discussed with 
Celgene.  Overall compliance with the study treatment regimen is defined as taking between 
75% and 120% of the expected doses during a subjectâ€™s participation while in the treatment 
phases (Placebo-controlled Phase and Apremilast Extension Phases) of the study.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21s) or or
in a in a 
access.access.
rsonnel thersonnel the
he sie site verste vii
nsing and dnsing and d
uments.uments.
anceance
inted on thnted on th
t will be dit will be di
to return tho return th
sit ft fior tablor tablfff
r IP as instrIP as inst
hh the subje the subjehh
ntacted to dntacted to 
ed from thed from th
up Phase.p Phase.
problems (problems (
doses betwdoses betw
erall call comomplpm
20% of 0% of ththe
(Pl(Pacebocebo --cc
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 49 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879184] its metabolism, 
pharmacokinetics (PK), or excretion, please see the Investigatorâ€™s Brochure and/or local package insert.
8.1. Permitted Concomitant Medications and Procedures
Subjects may take any med ication that is not restricted by [CONTACT_655105].  Chronic medication should be dosed on a stable regimen.
All medications (prescription and non-prescripti on), treatments and th erapi[INVESTIGATOR_655073], including those initiated prior to the start of the study, must be recorded on the subjectâ€™s source document and on the 
appropriate page of the eCRF.  The dose, unit, frequency, route, indication, the date the 
medication was started and the date the medication was stopped (if not ongoing) must be recorded.  The recording of any permitted topi[INVESTIGATOR_477042].
The following topi[INVESTIGATOR_477043]:
!For body lesions: unmedicated emollients
!For scalp lesions: non-medicated shampoos 
8.2. Prohibited Concomitant Medications and Procedures
The following psoriasis medications cannot be administered for the duration of the study:
!Topi[INVESTIGATOR_8588]
!Topi[INVESTIGATOR_8588], including, but not limited to, topi[INVESTIGATOR_11930], retinoids or 
vitamin D analog preparations, tacrolimus, pi[INVESTIGATOR_031], or anthralin/dithranol 
for body lesions; coal tar, salicylic acid preparations, or medicated shampoos for 
scalp lesions, or as specified in Section 8.1.
!Intralesional corticosteroid injections for psoriasis lesions
!Conventional systemic therapy
!Systemic therapy including but not limited to cyclosporine, corticosteroids, 
methotrexate, retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, 
sulfasalazine, azathioprine, or fumaric acid esters
!Phototherapy
!UVB or PUVA 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21dicaticatioon n 
aken by [CONTACT_655106], the dan, the d
not ongoinnot ongo
ken for psoken for pso
e frequencyfrequenc
the studyhe study :
mpoos mpoos
MeMedicatiodicati
nnot be adnot be ad
y, includingy, includin
nalog prepaalog prep
lesiesons; cos; c
esiesionons, or as, o
esisiononalal cortcorll
ConventionaConventiona
!SySysts
m
!
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 50 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017!Biologic agents, including:
!TNF or IL-17 blockers, anti-IL-12 or anti-IL-23 monoclonal antibodies or 
biosimilars for each 
!Use of any investigational drug or device
!Prolonged sun exposure or any use of tanni ng booths or other ultraviolet light sources
8.3. Required Concomitant Medication
Not applicable.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 51 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879185] (CC-[ZIP_CODE]) in subjects with moderate to severe plaque 
psoriasis of the scalp. Treatment assignment will be stratified by [CONTACT_655107] 
[moderate (3), or severe (4)]. 
The objective of the statistical analysis will be to evaluate the efficacy and safety of apremilast 
[ADDRESS_879186] completed the Placebo-controlled Phase (Weeks 0 to 16), the primary 
analysis will be performed.  At the study comple tion, ie, when all subjects have also completed 
the Apremilast Extension Phase (Weeks 16 to 32) and the Observational Follow-up Phase, the final analysis will be performed. To maintain the blind at the site and subject level, the individual 
subject treatment assignments will not be revealed to the investigators until after the final 
database lock following the study completion.
9.2. Study Population Definitions
The safety population will consist of all subjects who are randomized and received at least one 
dose of IP (IP).  Subjects will be included in the treatment group corresponding to the IP they actually receive.
The intent-to-treat (ITT) population will consist of all sub jects who are randomized. Subjects 
will be included in the treatment group to which they are randomized.
The per protocol (PP) population will consist of all subjects included in the ITT population who 
receive at least one dose of IP (IP), have both baseline and at least one post-treatment ScPGA 
evaluation, and have no protocol deviations which may affect analyses in the Placebo-controlled 
Phase.
9.3. Sample Size and Power Considerations
The sample size est imation is based on the results of the Phase [ADDRESS_879187] 30 mg BID and placebo in the proportion of subjects achieving ScPGA 
response at Week 16 (range 18% to 29%). Approximate ly 300 subjects will be randomized in a 
2:[ADDRESS_879188] 90% pow er to detect a minimum treatment difference of 
18% (38% for apremilast 30 mg BID versus 20% for placebo) between the two arms for 
proportions of subjects achieving ScPGA response at Week 16 (defined as ScPGA score of clear [0] or almost clear [1] with at least a 2 point reduction from baseline at Week 16).
If at least 60% of the approximate 300 randomized subjects would be evaluable for the whole 
body itch NRS an alysis, the subset sample size of 180 subjects will provide 90% power to detect 
a treatment difference of 25% (45% for apremila st 30 mg BID and 20% for placebo) in the 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21st 
BID asID as
he scalp.he scalp.
e primary e primary 
also comalso com plplm
oow-w-up Phasup Pha
ect level, thct level, th
until after thuntil after
andomizedndomize
ent group cent group 
of f all all subjesubje
ich theych they areareyy
nsist of all snsist of all s
vebothboth basas
viatiiationons s whw
and Pownd Pow
ttioion n is basis bas
PSORSOR --[ADDRESS_879189] 30 mg B
Week 16 (rek 16 (r aa
apremilastapremilast
05 siignificagnific
(38% for (38% for a
oportioporti ons oons o
[0]0]or almalm
at ltl
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 52 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017proportion of subjects with â‰¥4-point improvement from baseline in the whole body itch NRS 
score.
9.4. Background and Demographic Characteristics
Subjectâ€™s age, height, weight, and baseline char acteristics will be summar ized using descriptive 
statistics, while sex, race and other categorical variables will be provided using frequency 
tabulations.  Medical history data will be summarized using frequency tabulations by [CONTACT_10607] (MedDRA) system organ class and preferred term.
9.5. Subject Disposition
Subject disposition (analysis population allocat ion, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency tabulations and percent for the Placebo-controlled Phase (Weeks 0 to 16) and the Apremilast Extension Phase (Weeks 16 to 32).  
A summary of subjects enrolled by [CONTACT_27707]. Protocol deviations will be summarized 
using frequency distributions.
9.6. Efficacy Analysis
9.6.1. Efficacy Evaluation for the Placebo-controlled Phase (Weeks 0 to 16)
Statistical comparisons will be made between apremilast 30 mg BID and placebo. All statistical 
tests will be at the 2-sided 0.05 significance level and the corresponding p-values will be 
reported. Data summaries will be provided for the two randomized treatment arms (apremilast 30 
mg BID and placebo).
[IP_ADDRESS]. Primary Efficacy Endpoint
The primary endpoint is the proportions of subjects who achieving ScPGA response at Week 16 
(defined as ScPGA score of clear [0] or almost cl ear [1] with at least a 2-point reduction from 
baseline at Week 16).  It will be analyzed using the  ITT population. A sensitivity analysis will be 
performed using the PP population. 
The treatment difference between apremilast 30 mg BID and placebo will be compared using 
CMH (Cochranâ€“Mantelâ€“Haenszel) test adjusting for the stratification factor at randomization. 
The 2-sided p-values from the CMH test, the adjusted treatment difference in proportion using 
the weighted average of the treatment differences across the strata with the CMH weights, along with the associated 2-sided 95% CIs using a nor mal approximation to the weighted average will 
be provided. Missing values at Week 16 will be imputed using the multiple imputation (MI) 
method (SAS Institute Inc. 2008) as the primary analysis, with sensitivity analysis using the last 
observation carried forward (LOCF) met hod and the non-responder imputation (NRI) method.
The SAS procedure MI will be used to impute missing ScPGA scores at the scheduled 
assessments in the Placebo-controlled Phase (Week s 0-16) to create M=25 complete data sets. 
The missing data patterns will be checked by [CONTACT_655108] 
(Week 0), and Weeks 2, 4, 8, 12 and 16. If there are non-monotone missing patterns, two 
separate imputation procedures will be used to complete the imputation process. 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21h primaryh primary
ercent for trcent for 
(Weeks 16(Weeks 
s will be s will be sus
Phase (WePhase (W
30 mg BID30 mg BID
the correspthe corresp
wo randomwo random
s of subjectof subjec
]or almoor almo st
analyzed usanalyzed u
tioion. n. 
between aprween apr
lâ€“â€“HaenszelHaensze
 frofrom m ththe Ce
rage of the rage of the 
ated 2ated 2 -sisided
d.Missing Missing 
(SAS InstitAS Insti
vatvatioion carrin carr
he SAS prohe SAS pro
assessmessessme
he hemm
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 53 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879190] step, the Markov Chain Monte Carlo (MCMC) method will be used to impute missing 
scores by [CONTACT_655109] M=[ADDRESS_879191] observations to be used in the selection will be K=2. 
After the completion of imputation, the same CMH method will be used to analyze the [ADDRESS_879192] ical inferences.
[IP_ADDRESS]. Secondary Efficacy Endpoints 
For the binary endpoints defined as â‰¥4-point reduction (improvement) from the baseline visit in 
either the whole body pruritus NRS score or the scalp pruritus NRS score at post-baseline visits, 
the analyses will be based on subjects in th e ITT population with ba seline whole body pruritus 
NRS score â‰¥4 or baseline scalp pruritus NRS score â‰¥4, respectively. For the continuous 
secondary endpoint (ie, change from baseline in  DLQI total score at Week 16), the analyses will 
be based on ITT population. Unadjusted 2-sided p-values and 2-sided 95% confidence intervals 
(CIs) will be reported.
In order to evaluate the onset of effect of apremilast 30 mg BID compared to placebo for itch, the 
following secondary endpoints are specified (Section 2):
!Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the 
whole body itch NR S score at Week 16
!Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the 
scalp itch NRS score at Week 16
!Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the 
overall body itch NRS score at Week 12, Week 8, Week 4, and Week 2
!Proportion of subjects with â‰¥4-point reduction (improvement) from baseline in the 
scalp itch NRS score at Week 12, Week 8, Week 4, and Week [ADDRESS_879193] from Week 16 
to Week 2. Multip licity adjustment is sp ecified in Section [IP_ADDRESS] . 
The binary endpoints will be analyzed similarly as the primary endpoint. The treatment 
difference at each time point between apremilast 30 mg BID and placebo will be compared using 
CMH (Cochranâ€“Mantelâ€“Haenszel) test adjusting for the stratification factor at randomization.
The 2-sided p-values from the CMH test, the adjusted treatment difference in proportion using the weighted average of the treatment differences across the strata with the CMH weights, along 
with the associated 2-sided 95% CIs using a nor mal approximation to the weighted average will 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e 
ous us 
e the the 25 25 
ine the resune the re
ent) from thent) from 
NRS score NRS s
wiwiththiii b hhaselisel
spectively.spectively.
total scoretotal score
alues and 2alues and
emilastemilast 30 30
ed (ed (SectionSectio
hhâ‰¥4â‰¥4--poinpotn
core at Were at We
ects wiects wi ththiiiâ‰¥4â‰¥
core at Wecore at W
ofof subjects subjectsff
odydyititchchNN
portiportion ofon of suff
calp calp ititchchNRNR
al analyses nalyse
ek 2. Multek 2. Mult
he binary ehe binary 
differencedifferenc
MH MH
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 54 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017be provided. Missing values will be imputed using the similar MI method as the primary 
endpoint, with sensitivity analysis using the LOCF method and NRI method.
The continuous endpoint (ie, change from bas eline in DLQI total score at Week 16) will be 
analyzed based on the ITT population using the analysis of covariance (ANCOVA) model. The ANCOVA model will use the change from baseline as the dependent variable and will include 
treatment group and stratification fact or as independent variables and the baseline value as a 
covariate variable. Within- group least-squa res (LS) mean changes from baseline at Week 16, the 
associated standard errors (SEs) and 2-sided 95% CIs, treatment differences in LS mean changes 
from baseline, and the associated 2-sided 95% CIs  and p-values, will be derived from the 
ANCOVA model. Missing values at Week 16 will be imputed using the MI method, with sensitivity analysis using the LOCF method.
[IP_ADDRESS]. Multiplicity Adjustment
The primary and secondary efficacy endpoints will be hierarchically ranked for testing in order 
to control the overall type I error rate in claiming statistical significance at the 2-sided 0.05 
significance level.  Specifically, for the primary efficacy endpoint (ScPGA response at Week 
16), if the 2-sided p-value from the comparison between apremilast [ADDRESS_879194] sequence for the 
primary and secondary efficacy endpoints is listed as the following:
!Proportion of subjects with ScPGA score of cl ear (0) or almost clear (1) with at least 
a 2-point reduction from baseline at Week 16
!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
whole body itch NR S score at Week 16
!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
scalp itch NRS score at Week 16
!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
whole body itch NR S score at Week 12
!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
scalp itch NRS score at Week 12
!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
whole body itch NR S score at Week 8
!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
scalp itch NRS score at Week 8
!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
whole body itch NRS score at Week 4
!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
scalp itch NRS score at Week 4
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21es es 
h 
for testing for testing
the 2the 2 -siided
PGA responGA respo
30 mg BID0 mg BID
nt and apreand apr
ical significcal signi
imary endpmary end
evel. vel. The pThe 
the fothe fo llollow
core of cleaore of clea
t Week 16t Week 16
point redupoint redu
at Week 1t Week 1
withthiâ‰¥4 poi poi
 at Week 1at Week 1
ubjects wibjects wi thtii
chchNRS scRS 
n ofn of subje subjeff
ttchchNRS sNRS s
roportiroporti on oon o
whowholelebobo
!!PropoProp
scsc
!
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 55 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
whole body itch NRS score at Week 2
!Proportion of subjects with â‰¥4 point reduction (improvement) from baseline in the 
scalp itch NRS score at Week 2
!Change from baseline in Dermatology Life Quality Index total score at Week 16
[IP_ADDRESS]. Exploratory Endpoints 
Descriptive summary statistics or proportion of subjects achieving specified criteria will be 
summarized by  [CONTACT_1570]. When a ppropriate, exploratory endpoints at Week 16 will also 
be analyzed using CMH or ANCOVA methods similar to the primary and secondary endpoints.
[IP_ADDRESS]. Subgroup Analysis 
Subgroup analyses for ScPGA response at Week 16 and proportions of subjects with â‰¥4-point 
reduction (improvement) from baseline in the w hole body itch NRS or scalp itch NRS scores at 
post baseline time points based upon baseline dem ographic (age, gender, race, etc.) or baseline
disease characteristics will be provided to determine the robustness of the treatment effect.
 
 
 
9.6.2. Efficacy Evaluation â€“ Apremilast Extension Phase (Weeks 16 to 32)
Efficacy endpoints for time points beyond Week 16 will be summarized according to the 
treatment assigned at randomization. For all subj ects, changes in measurements will be 
calculated relative to measurements obtained  at baseline (Week 0). Descriptive summary 
statistics or proportion of subjects achieving specified criteria will be summarized by [CONTACT_1570]. For continuous variables, descriptive statis tics for baseline and changes or percent 
changes from baseline will be provided. Categorical variables will be summarized with 
frequency tabulations. 2-sided 95% confidence in tervals will be provided for changes or percent 
changes and response rates.
9.7. Safety Analysis
The safety analyses will be performed using the safety population as  defined in Section 9.2. 
Safety will be assessed by [CONTACT_477052]-emergent adverse events (TEAEs), laboratory tests, vital signs, and ECG 
measurements; no inferential testing for statist ical signif icance will be performed.
Adverse events will be classified using the Medical Dictionary for Regulatory Activities 
(MedDRA) classification system. Adverse events will be tabulated for the Placebo-controlled 
Phase (Weeks 0 to 16) and the Apremilast Expos ure Phase in the study. All TEAEs will be 
summarized by [CONTACT_9313], preferred term, severity, and relationship to IP.  Adverse 
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21l also l also 
ndpondpo intints.s.
cts wicts w thhiâ‰¥4â‰¥[ADDRESS_879195] Exte
yoyond Weeknd W
n.For all sFor all s
ents obtainents obtain
bjects achiebjects achie
riables, desciables, des
will be prowill be pro
ns.2-2-sidedsided
onse rates.onse rates.
Safety AnSafety An
fetety yanalysenalys
tty y will be awill be 
eatmeatm entent--eme
measuremmeasurem$5<7$57$(7$5,(7
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 56 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879196] completed the Week 16 Visit (or discontinued from the study), a Week [ADDRESS_879197] Research Organization (CRO) team members involved with 
analysis of the data   All other Sponsor, 
site, and CRO personnel directly involved with the conduct of the study, will remain blinded to treatment assignments until the final database lock at the conclusion of the study.  At the end of 
the study, after all sub jects have completed, or have been discontinued from the Apremilast 
Extension Phase (Weeks 16 to 32) and the Observational Follow-up Phase, the final analysis will be performed and a final Clinical Study Report will be generated.
9.9. Other Topi[INVESTIGATOR_1102]
9.9.1. Investigational Product Compliance (Tablets)
Investigational product record information will be summarized.  Overall compliance will be 
estimated by [CONTACT_198518] 75% and 120% of the intended 
quantity of IP.
9.9.2. Concomitant Therapy
All concomitant treatments documented during the study period will be summarized in frequency 
tabulations. The Anatomical Therapeutic Chemical (ATC) coding scheme of the World Health Organization (WHO) will be used to group me dications into releva nt categories for these 
tabulations.
9.9.3. Steering Committee 
Guidance in protocol development and inter pretation of data analysis will be provided by a 
scientific steering committee (SSC).  Det ails for the SSC are pre-s pecified in a separate SSC 
charter.
CCICCI
CCI
CCI
&(/*(1([ZIP_CODE],(7$5<of the studyof the stud
onclusionclusio n n
en disconten discont ii
ional Foional Fo lloll
wilill l be generbe gene
CompliancComplianc
ormatormat ion wn 
subjects whubjects w
ant Therapnt Therap
eatmeatm ents dents d
e Anatomice Anatomic
n (WHO) wn (WHO) w
s.
.. SteeSte
GuiGuidance idance i
scientificientif
art<,1)250$7,21the studythe study ),),yy
cted ted 
ll only be mll only be m
m members imembers1)2CCI
5<,
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 57 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879198] Program: Role of the 
Safety Management Team 
In addition to daily safety monitoring conducted by [CONTACT_198516], 
cumulative and interval blinded adverse events  (AEs), serious adverse events (SAEs),
discontinuations, and laboratory findings are reviewed internally by a Safety Management Team
(SMT) at Celgene. The review follows the Council for International Organizations for Medical Sciences, Working Group VI (CIOMS VI) recommendations. The SMT is comprised of lead 
representatives from multiple Celgene functions engaged in the apremilast development 
program. The scope, conduct, processes, and accountabilities of the SMT are specified in theSMT charter.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 58 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879199]â€™s health, including 
laboratory test values (as specifi ed by [CONTACT_14540] 10.3), regardless of etiology. Any 
worsening (ie, any clinically significant adverse ch ange in the frequency or intensity of a pre-
existing condition) should be cons idered an AE.  A diagnosis or syndrome should be recorded on 
the AE page of the case report form (CRF) rather than the individual signs or symptoms of the 
diagnosis or syndrome. 
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be reported on the overdose CRF. (See Section 7.3for the definition of overdose.) Any sequela of 
an accidental or intentional overdose of an investigational product should be reported as an AE 
on the AE CRF. If the sequela of an overdose is an SAE, then the sequela must be reported on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be identified 
as the cause of the event on the SAE report form and CRF but should not be reported as an SAE 
itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary.  There is no known specific antidote for apremilast overdose. 
Actual treatment should depend on the severity of the clinical situation and the judgment and experience of the treating physician.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters: the subjectâ€™s clinical symptoms, laboratory, pathological, radiological or surgical findings , physical examination findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by [CONTACT_292004] [ADDRESS_879200]â€™s source documents.  All SAEs must be reported to Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by [CONTACT_6972], 
or other appropriate method, using the SAE Report Form, or approved equivalent form.  
10.2. Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to: 
10.2.1. Seriousness 
An SAE is any AE occurring at any dose that:
!Results in death;
!Is life-threatening (ie, in the opi[INVESTIGATOR_689], the subject is at immediate 
risk of death from the AE);
CCIed on d on
of f ththe e
reported aseported as
n AE shoulAE shou
ose.)ose.) Any sAny 
dbe reportebe rep
quela must buela must 
n the SAE sthe SAE
hould not bhould not b
d as appropas appr
specific anspecific an
hhe clinical e clinical
ng the studyng the study
ththe subjece subjec
findings, phfindings, ph
e InvestiInvesti gatgat
ose of IPose of IP as
re suspectere suspe
RF and in thF and in th
y ywiwiththiiin 24in 2
iate methodiate metho
EvaluatiEvaluati
ified Invesified Inves
[IP_ADDRESS].2.1. S
An SAEAn SA
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 59 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017!Requires inpatient hospi[INVESTIGATOR_27588] 
(hospi[INVESTIGATOR_19357], regardless of length of stay);
!Results in persistent or significant disability/incapacity (a substantial disruption of the 
subjectâ€™s ability to conduct normal life functions);
!Is a congenital anomaly/birth defect;
!Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life-
threatening or result in death, hospi[INVESTIGATOR_059], or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be considered serious.
Events not considered to be SAEs are hospi[INVESTIGATOR_5315]:
!a standard procedure for protocol therapy administration.  However, hospi[INVESTIGATOR_184607] d hospi[INVESTIGATOR_272] a complication of therapy administration will be 
reported as an SAE. 
!routine treatment or monitoring of the stud ied indication not associated with any 
deterioration in condition.
!the administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospi[INVESTIGATOR_27589] a complication 
of such transfusion remains a reportable SAE.
!a procedure for protocol/disease-related investig ations (eg, surgery, scans, endoscopy, 
sampling for laboratory tests, bone marrow sampling).  However, hospi[INVESTIGATOR_184607] d hospi[INVESTIGATOR_272] a complication of such procedures remains a reportable 
SAE.
!hospi[INVESTIGATOR_27591], practical, or social 
reasons, in absence of an AE.
!a procedure that is planned (ie, planned prior to start of treatment on study); must be 
documented in the source document and the CRF.  Hospi[INVESTIGATOR_72613] a complication remains a reportable SAE.
!an elective treatment of or an elective pro cedure for a pre-existing condition, 
unrelated to the studied indication, that has not worsened from baseline. 
!emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to the IP, action taken regarding the IP, and outcome.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21or 
ve.  ve.  
E should beE should be
wever, hospwever, hos
ministratiinistrati ono
ation not astion n
usioion nas rouas ro
rolonged horolonged
e SAE.e SAE.
llated invesated inves
one mne m arrowarrow
a coma com plicplmmm
ongationgati on oon 
e of an AE.e of an AE
at is planneat is pla
d in the soud in the sou
zatiation fon for or fff
ectective treaive trea
nrelated to nrelated to
eemergemerge
unlesunl
f an AE if an AE i scs
must be cmust be c
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 60 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 201710.2.2. Severity/Intensity
For both AEs and SAEs, the Investigator must assess the severity/ intensity of the event based on 
the descriptions listed below. 
Mild
!Asymptomatic or mild symptoms; clinical or diagnostic observations only
!Intervention not indicated
!Activities of daily life (ADLs) minimally or not affected
!No or minimal intervention/therapy may be required 
Moderate 
!Symptom(s) cause moderate discomfort
!Local or noninvasive intervention indicated
!More than minimal interference with ADLs but able to carry out daily social and 
functional activities.
!Drug therapy may be required
Severe (could be non-serious or serious) 
!Symptoms causing severe discomfort/pain
!Symptoms requiring medical/surgical attention/intervention
!Interference with ADLs including inability to perform daily social and functional 
activities (eg, absenteeism and/or bed rest)
!Drug therapy is required
The term â€œsevereâ€ is often used to describe th e intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is notthe same as â€œseriousâ€ which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subjectâ€™s life or functioning.  
Seriousness, not severity, serves as a gui de for defining regulatory obligations.
10.2.3. Causality
The Investigator must determine the relationship between the administration of the IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: a causal relationship of the adverse event to IP administration is 
unlikely or remote , or other medications, therapeutic 
interventions, or underlying c onditions provide a sufficient 
explanation for the observed event.
Suspected: there is a reasonable possibility that the administration of IP 
caused the adverse event.  â€˜Reasonable possibilityâ€™ means there 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21y out daily y out daily
ttention/intttention/in
nability to pability to p
r bed rest)r bed rest)
describe thescribe th
; the event ; the event 
headache).  eadache). 
come ome or oacac
ning. ning.
veritrity,y, serv serv
ausalityusality
tigator musgator mus
ence of an Ance of an A
Not Not 
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 61 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879201] a causal relationship between the IP and 
the adverse event.
Causality s hould be a ssessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by [CONTACT_27718], please provide the name [CONTACT_27765].
10.2.4. Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
10.2.5. Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation, interruption, or dose reduction of IP, as appropriate) and report if 
concomitant and/or additional treatments were given for the event. 
10.2.6. Outcome
The Investigator will report the outcome of the event for both AEs and SAEs.All SAEs that have not resolved upon discontinuation of the subjectâ€™s participation in the study 
must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to 
the SAE).
10.3. Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!results in discontinuation from the study;
!requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or
!is judged to be of significant clinical importance, eg, one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing condition.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a 
part of a diagnosis or syndrome, then the labor atory abnormality should be r ecorded as the AE. If 
possible, the laboratory abnormality should be r ecorded as a medical term and not simply as an 
abnormal laboratory result (eg, record throm bocytopenia rather than decreased platelets).
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21dates of thdates of th
AE or SAE, E or SAE
priate) and priate) an
nt. 
or both AEor both AE
oon of the sn of the s
aseline), recaseline), r
 ValuesValues
nsidered tosidered t
uatatioion n fromfrom
ent, mnt, m odifiodifi
; or; or
d to be of sd to be of s
ess and/or oess and/or 
ndidititiiiion.on.
ss of severiof sever
o be documo be docum
a laboratora laborator
or syndromor syndrom
art of art of
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 62 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879202] of childbearing potential 
are immediately reportable events .
Pregnancies and suspected pregnancies (including elevated Î²-subunit of human chorionic 
gonadotropin [ Î²-hCG] or positive pregnancy test in a female subject of childbearing potential 
regardless of disease state) occurring while the sub ject is on IP, or within [ADDRESS_879203]â€™s 
last dose of IP, are considered immediately reportable events.  Investigational product is to be 
discontinued immediately and the subject instructed to return any unused portion of the IP to the investigator.  The pregnancy, suspected pregnancy,  or positive pregnancy test must be reported to 
Celgene Drug Safety immediately by [CONTACT_6968], phone or facsimile, or other appropriate method, 
using the Pregnancy Initial Report Form, or approved equivalent form.  
The female subject may be referred to an obstetrician-gynecologist or another appropriate 
healthcare professional for further evaluation.
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow -up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE.  If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by [CONTACT_6972], or other appropriate
method, within 24 hours of the Investigatorâ€™s knowledge of the event using the SAE Report Form, or approved equivalent form.
All neonatal deaths that occur within [ADDRESS_879204] to 
causality, as SAEs.  In addition, any infant deat h after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by 
[CONTACT_6972], or other appropriate method, within 24 hours of the Investigatorâ€™s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
10.5. Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the CRF.  All SAEs must be reported to 
Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by [CONTACT_6972], or other appropriate method (eg, via email), using the SAE Report Form, or approved equivalent 
form.  This instruction pertains to initial SA E reports as well as any follow-up reports.
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
(from the time the subject signs i nformed consent until [ADDRESS_879205] dose of IP) or any 
SAE made known to the Investigator at any time thereafter that are suspected of being related to IP.  Serious adverse events occurring prior to treatment (after signing the ICF) will be captured.
The SAE report should provide a detailed description of the SAE and include a concise summary 
of hospi[INVESTIGATOR_27598].  If a subject died and an autopsy has been performed, copi[INVESTIGATOR_493054] h certificate are to be sent to Celgene Drug 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21the the 
orted to orted to 
ethodethod , , 
ppropriate ppropriate 
egnancyegnanc , any
gnancygnancy (ei(eiyyti
r approvedr approve
s abortion)abort
mal outcommal outcom
afetafety yby [CONTACT_655110] f ththe eee
f birth shoubirth sho
death after 2eath after [ADDRESS_879206] approve
erious Aderious A
riterion for riterion 
ded on the ded on the
y wiwiththiiin 24in 24
ate methodate method
struction peruction p
tigator is regator is r
quirement quirement 
m m ththe time e time 
AE mAE m ade kade 
IP.  SeriP.  Seri
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 63 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879207]/Ethics Committee (IRB/EC) of the SAE and providing them with all relevant initial and follow-up information about the event. The Investigator must keep copi[INVESTIGATOR_184609]/EC.
10.5.1. Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (eg, missing causality assessment) may be handled by [CONTACT_648].
10.6. Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of events suspected of being related to a premilast based on the Investigator Brochure.
In the [LOCATION_002], all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
Celgene or its authorized represe ntative shall notify the Investigator of the following information 
!Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (eg, S[LOCATION_003]R);
!Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by [CONTACT_19666], the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copi[INVESTIGATOR_184610]/EC.  (See Section 14.[ADDRESS_879208] retention 
information).
Celgene Drug Safety Contact [CONTACT_7171]:
For Celgene Drug Safety contact [CONTACT_3031], please refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pr egnancy Report Form Completion Guidelines.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21business siness 
e the expece the expe
Brochure.Brochu
ons (SUns (SU SASA
32.2.
ttigator of tigator of
of IP in thiof IP in 
[LOCATION_003]R);[LOCATION_003]R);
nimals that nimals tha
f mutagenicmutageni
vestvestigator sigator 
) or signifior signi
of all pertf all pert ini
d the IRB/Ed the IRB/
ontact Infontact I
fetfety y contacconta
GuidelinesGuidelines
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 64 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879209](s):
!Adverse event
!Lack of efficacy
!Withdrawal by [CONTACT_1130]
!Death
!Lost to follow-up
!Non-compliance with IP
!Protocol deviation
!Pregnancy
!Physician decision
!Study terminated by [CONTACT_2728]
!Other (to be specified on the CRF)
The reason for discontinuation of treatment should be recorded in the CRF and in the source 
documents.
When a subject is discontinued from treatment, the Investigator should make every attempt 
possible to have the subject evaluated at the Ear ly Termination Visit within [ADDRESS_879210] from the study:
!Screen failure
!Adverse event
!Withdrawal by [CONTACT_1130]
!Death
!Lost to follow-up
!Protocol deviation
CCIbe recordedbe recorde
nt, the Invent, the Inve
he Early Tehe Early T
ect frofm m tre
ayed or refayed or ref
ay contact [CONTACT_198522] t
diiscussiscus on
Discontiniscontin
events are cvents are c
Screen fScreen 
!AdAd
!!
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 65 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017!Pregnancy
!Physician decision
!Study terminated by [CONTACT_2728]
!Other (to be specified on the CRF)
The reason for study discontinua tion should be r ecorded in the CRF and in the source 
documents.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 66 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879211] the responsible Clinical Research 
Physician/Medical Monitor or designee by [CONTACT_27722](s) listed on the Emergency 
Contact [CONTACT_27723] (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact [CONTACT_27724] (after title page). This global 
Emergency Call Center is available 24 hours a day and 7 days a week. The representatives are 
responsible for obtaining your call-back information and contact[CONTACT_81694]-call Celgene/contract 
research organization Medical M onitor, who will then contact [CONTACT_27726].
Note: The back-up 24-hour global emergency contact [CONTACT_292053](s) or Medical Monitor or designee for 
emergency calls. 
12.2. Emergency Identification of Investigational Products
The blind must not be broken during the course of the study unless in the opi[INVESTIGATOR_684], it is absolutely necessary to safely treat the subject.  If it is medically imperative to 
know what IP the subject is receiving, IP should be temporarily discontinued if, in the opi[INVESTIGATOR_689], continuing IP can negatively affect the outcome of the subjectâ€™s treatment.
The decision to break the blind in emergency situations remains the responsibility of the treating 
physician, which will not be delayed or refused by [CONTACT_1034].  However, the Investigator may contact [CONTACT_81695], mainly in the 
interest of the subject. 
The Investigator should ensure that the code is  broken only in accordance with the protocol. The 
Investigator should promptly notify the Medical Monitor of the emergency unblinding and the 
reason for breaking the blind, which should be clearly documented by [CONTACT_292054]â€™s source documentation.
Emergency unblinding should only be performed by  [CONTACT_292055] (PIN), and the Investigator should contact
[CONTACT_655111].
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21be e 
on 
ves are ves are 
ene/ene/contracontra
bbe used if ye used if 
r designee fdesignee f
ProductsProduct
nlessnless in thin t
ubject.  If itject.  If i
porarily disporarily d
the outcomthe outco
uations remuations rem
ed by [CONTACT_655112] S
ing the blinng the bli
the code ishe code i
tify the Meify the Me
which shouwhich sho
ation.ion.
g shoulshou d onon
ng personag persona
d dose infod dose info
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 67 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879212], evaluation, and 
documentation of this study are designed to ens ure that Celgene, its authorized representative, 
and Investigator abide by [CONTACT_23663] (GCP), as described in International Council for
Harmonisation (ICH) Guideline E6 and in accordance with the general ethical principles outlined in the Declaration of Helsinki. The study will  receive approval from an IRB/EC prior to 
commencement. The Investigator will conduct all aspects of this study in accordance with 
applicable national, state, and local laws of the pertinent regulatory authorities.
13.2. Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in the local regulations. Celgene staff or an authorized representative will evaluate and approve all Investigators who in turn will select their staff.
The Investigator should ensure that all persons assi sting with the study are adequately informed 
about the protocol, amendments, study treatments,  as well as study-related duties and functions, 
including obligations of confidentiality of Celgene information. The Investigator should maintain 
a list of Sub-investigators and other appropriately qualified persons to whom he or she has 
delegated significant study-related duties.
The Investigator is responsible for keepi[INVESTIGATOR_007] a record of all subjects who sign an informed consent 
form (ICF) and are screened for entry into the study .  Subjects who fail screening must have the 
reason(s) recorded in the subjectâ€™s source documents.
The Investigator, or a designated member of the Investigatorâ€™s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospi[INVESTIGATOR_1332], and study-related charts) for source data verification.  The Investigator must ensure timely and accurate completion of CRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by [CONTACT_184689]) is considered Celgene confidential 
information.  Only information that is previously disclosed by [CONTACT_184690] a public registry 
website may be freely disclosed by [CONTACT_655113], or as outlined in the Clinical 
Trial Agreement.  Celgene protocol, amendment a nd IB information is not to be made publicly 
available (for example on the Investigatorâ€™s or their institutionâ€™s website) without express written 
approval from Celgene.  Information propos ed for posting on the Investigatorâ€™s or their 
institutionâ€™s website must be submitted to Celgene for review and approval, providing at least [ADDRESS_879213] and/or their caregiver as agreed by [CONTACT_1560].
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21Practice anPractice 
luate and aluate and a
dyy are adeqare adeqyy
y--related drelated d
. The InvesThe I
persons to persons to 
of all subjeof all sub
dydy.  Subjec.  Subje
ments.ments.
of the Invesf the Inve
e queries anqueries 
alal charts, achartsll
st ensure timst ensure 
the protocothe protoc
elgene on pgene on 
mmataion than th
y disclosedy disclose
CelCelgene prgene pr
xample on xample o
mmCelCelmm genegene
nâ€™s websitewebsite
ss days forss days for
the time rethe time r
Investnvest igatigat
esponsespon
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 68 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879214] and/or a subjectâ€™s legal representative 
prior to any study related procedures.
Documentation that informed consent occurred prior to the study subjectâ€™s entry into the study 
and of the informed consent process should be recorded in the study subjectâ€™s source documents including the date.  The original ICF signed and dated by [CONTACT_655114]â€™s entry into the study, must be maintained 
in the Investigatorâ€™s study files and a copy given to  the study subject.  In addition, if a protocol is 
amended and it impacts on the content of the informed consent, the ICF must be revised.  Study 
subjects participating in the study when the amended protocol is implemented must be re-
consented with the revised version of the ICF.  The revised ICF signed and dated by [CONTACT_292058] s ubject must be maintained in the Investigatorâ€™s 
study files and a copy given to the study subject.
13.4. Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (w hichever is most stringent). Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require  a waiver or authorization separate from the 
subjectâ€™s signed ICF, it is the responsibility of the Investigator to obtain such permission in writing from the appropriate i ndividual.
13.5. Protocol Amendments
Any amendment to this protocol must be approved by [CONTACT_184693]/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, protocol number, study title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
13.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protoc ol, ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is sought. If applicable, the documents will also be  submitted to the authorities in accordance with 
local legal requirements.
IP can only be supplied to an Investigator by [CONTACT_72648] a nd legal requirements for starting the study has been received by 
[INVESTIGATOR_70379]&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ol is ol is
Study Study 
re-
the studythe study
Investnvest igatoigato
privacyivacy ananydd
ost stringenst stringen
necessary, necessa
cords relevcords relev
iver or authver or au
InvestInve igatoiga
st be approvt be app
endments wndments 
ned beforened before
mm the IRB/E the IRBmm
tlle and ameand 
re do not ree do not re
poses.poses.
nstitutionnstitution
anand Appd App
e the e the start oart o
submitted tubmitted t
dates of issdates of iss
sought. ought
al
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 69 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879215] of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP. For example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by [CONTACT_1201]/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a commi ttee membe r. Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The Investigator must keep a record of all comm unication with the IRB/EC  and, if applicable, 
between a Coordinating Investigator [INVESTIGATOR_72616] /EC. This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by [CONTACT_27734]/EC prior to use.  
13.7. Ongoing Information for Institutional Review Board/ Ethics 
Committee
If required by [CONTACT_27735]/EC, the Investigator must submit to the IRB/EC:
!Information on serious or unexpected adverse events as soon as possible; 
!Periodic reports on the progress of the study;
!Deviations from the protocol or anything th at may involve added risk to subjects.
13.8. Termination of the Study
Celgene reserves the right to terminate this st udy prematurely at any time for reasonable medical 
or administrative reasons. Any premature discontinuation will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc.).
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!Unsatisfactory enrollment;
!GCP noncompliance;
!Inaccurate or incomplete data collection;
!Falsification of records;
!Failure to adhere to the study protocol.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21otocol ocol 
aluated to aluated to 
also be revalso be rev
and, if appand, if app
o applies toapplie
r, if applicar, if applic
be reviewee revi
onal Revienal Revie
vestigator mestigator 
pected advepected adv
gress of thegress of the
otocolotoco  or aorl
of the Stuof the S
ht to terminht to term
ons. ons. Any pAny
requirequi rereiiimenme
e InvestInvest igaig
studytudy ffyyor mor mff
!!UnsatUnsat ii
!!GG
!
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 70 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 201714. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] 
14.1. Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigat ional product are complete, accurate, filed and 
retained.  Examples of source documents include: hospi[INVESTIGATOR_1097]; clinic and office charts; 
laboratory notes; memoranda; subjectâ€™s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copi[INVESTIGATOR_27602]; microfiche; x-ray film and re ports; and records kept at the pharmacy, and 
the laboratories, as well as copi[INVESTIGATOR_655074], read only memory device (CD-
ROM).
14.2. Data Management
Data will be collected via CRF and entered into the clinical database per Celgene SOPs. This data will be electronically verified through use of programmed edit checks specified by [CONTACT_109396].  Discrepancies in the data will be brought to the attention of the clinical team, and 
investigational site personnel, if necessary.  Resolutions to these issues will be reflected in the database.  An audit trail within the system will track all changes made to the data.
14.3. Record Retention
Essential documents must be retained by [CONTACT_184694]. The Investigator must retain these documents for the time period described above or according to local laws or requirements, whichever is longer. Essential 
documents include, but are not limited to, the following:
!Signed ICFs for all subjects;
!Subject identification code list, screening log (if applicable), and enrollment log;
!Record of all communications between the Investigator and the IRB/EC;
!Composition of the IRB/EC;
!Record of all communications between the Invest igator, Celgene, and their authorized 
representative(s);
!List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;
!Copi[INVESTIGATOR_3110] (if paper) and of documentation of corrections for all subjects;
!IP accountability records;
!Record of any body fluids or tissue samples retained;
!All other source documents (subject records, hospi[INVESTIGATOR_1097], laboratory records, 
etc.); 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21s s 
, and and 
DD--
elgene SOPlgene SOP
ks specifieds spec
on of the clin of the cl
sues will beues will 
 made to thmade to th
ator accordiator accord
st retain thest retain th
quirementsquirements
follofollo wingwing
de list, screee list, sc
nicatinicati ons bons b
he IRB/EChe IRB/E
 cocommuunin
ative(s);tive(s);
f Subf Sub -inveinv
vestestigator higator 
thhe studye study
!!Copi[INVESTIGATOR_184614]
!!IPIP
!
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 71 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017!All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writi ng from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrang ements. Details of these arrangements should be 
documented. 
All study documents should be made availabl e if required by [CONTACT_27737]. 
Investigator or institution should take measures to prevent accidental or premature destruction of 
these documents.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ruction of uction of
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 72 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879216] to current GCP and SOPs.
15.1. Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after the study.  All aspects of the study are reviewed with the Investigator and the staff at a study initiation visit and/or at an Investigatorsâ€™ Meeting.  Prior to enrolling subjects into the study, a 
Celgene representative will review the protoc ol, CRFs, procedures for obtaining informed 
consent, record keepi[INVESTIGATOR_007], and reporting of AEs/ SAEs with the Investigator.  Monitoring will 
include on-site visits with the Investigat or and his/her staff as  well as any appropriate 
communications by [CONTACT_2319], email, fax, or telephone.  During monitoring visits, the facilities, 
investigational product storage area, CRFs, subjectâ€™s source documents, and all other study documentation will be inspected/reviewed by [CONTACT_292060].
Accuracy will be checked by [CONTACT_12939] a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the CRFs or via queries by [CONTACT_11219]/or his/her staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
15.2. Audits and Inspections
In addition to the routine monitoring procedure s, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene standard operating procedures (SOPs) to evaluate 
compliance with Good Clinical Practice guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by [CONTACT_1744]/ECs, regulatory  authorities (eg, FDA, European Medicines 
Agency [EMA], Health Canada) and company authorized representatives.  The Investigator should make every effort to be available for the audits and/or inspections.  If the Investigator is 
contact[CONTACT_655115], he/she should contact [CONTACT_184696].
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21a 
will will 
e e 
facilitcilities, ies, 
l other studother stu
accordanceaccordanc
t iis a dis a di recrecii
cumentationumentatio
/her staff.  /her sta
by [CONTACT_655116], adherents, adhe
ecording beecording b
ecific mecific m onion
cedures, cedures a GG
atives of thatives of th
ne e standardstandar
Practice guPractice gu
to permit dto permi
and applicand app
by [CONTACT_1744]/by [CONTACT_655117]..
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 73 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879217] authors hip, will be based on 
several considerations, including, but not limited to, contribution to protocol development, study 
recruitment, data quality, participation in data analysis, participation in study steering committee 
(when applicable) and contribution to abstract, presentation and/or publication development.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21es to s to 
al 
evelopmenevelopmen
maymay by[CONTACT_184697], as well aes, as we
h authorityh authority
thorship, wthorship, w
tion to protion to pro
rticipation icipation
tion and/ortion and/o
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 74 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 201717. REFERENCES
 
 
Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al.  Relapse, rebound 
and psoriasis adverse events: An advisory group report.  J Am Acad Dermatol.  2006;54:S171-
81.
Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF, et al.  Treatment of 
severe scalp psoriasis: From the medical board of the National Psoriasis Foundation.  J Am Acad 
Dermatol. 2009;6:962-71.
FDA Guidance for Industry E10.  Choice of control group and related issues in clinical trials.  
May 2001.
Feldman SR, Housman TS.  Patientsâ€™ vehicle preference for corticosteroid treatments of scalp 
psoriasis.  Am J Clin Dermatol.  2003;4(4):221-4.
Finlay AY, Khan GK.  Dermatology Life Quality Index (DLQI): a simple practical measure for 
routine clinical use.  Clin Exp Dermatol.  1994;19:210-6.
  
 
Griffiths, CE, Reich K, Lebwohl M, Kerkhof P, Paul C, Menter A, Cameron, GS, Erickson J, 
Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis 
(UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Lancet 2015; 
386:541-51.
Hogan DJ, Rooney ME.  Facial telangiectasia associ ated with long-term a pplication of a topi[INVESTIGATOR_655075].  J Am Acad Dermatol 1989;20:1129-30.
Kimball AB, Luger T, Gottlieb A, Puig L, Kaufma nn R, Nikai E,et al.  Impact of ix ekizumab on 
psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical 
trials.  J Am Acad Dermatol.  2016;75(6):1156-61.
Kragballe K, Menter A, Lebwohl M, Tebbey PW, van der Kerkhof PC.   Long-term management 
of scalp psoriasis: perspectives from the Inte rnational Psoriasis Council.  J Dermatol Treat.  
2013;24:188-92.
 
Lebwohl M. Psoriasis.  Lancet.  2003a;361:1197-204.
CCICCI
CCICCI
CCI
&(/*(1([ZIP_CODE],(7$5<of P, Paul Cf P, Paul C
OsuntokunOsuntokun
ercept or plercept o
: resulre ts fts flrrfff
cicialaltelangitelanll
p.  J p. Am AmA
T, Gottlieb , Gottlieb
riitytyiii and and yy otot
cad Dermacad Derm
K, Menter K, Menter 
psoriasis: psoriasis: 
;24:188;24:188 -92-97$5(7$
(/*&(&(I5<,1)250$7,21ent of nt o
m Acad m Acad 
inical trialsnical trial
treatments treatments
simple pracmple prac
5<
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 75 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: [ADDRESS_879218] Itch Numeric Rating 
Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis.  Int J Dermatol 
2015;54:715-22.
Ortonne JP, Chimenti S, Luger T, Puig L, Reid F, Tr Ï‹eb RM. Scalp psoriasis: European 
consensus on grading and treatment algorithm. JEADV 2009;23:1435-44.
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, Augustin M, Szepi[INVESTIGATOR_22938], StÃ¤nder S. 
Assessment of pruritus intensity: prospective study on validity and reliability of the visual 
analogue scale, numeric rating scale and verbal ra ting scale in 471 patients with chronic pruritus. 
Acta Derm Venereol. 2012; 92:502-7.
Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, Goldblum O, Dennehy EB, 
Kerr L, Sofen H. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, 
UNCOVER-3). J Dermatolog Treat. 2016 Nov 13:1-6. [Epub ahead of print]
SAS Institute Inc. 2008. SAS/STAT
Â®9.2 Userâ€™s Guide. Cary, NC: SAS Institute Inc.
Szepi[INVESTIGATOR_110425], JC, Reich, A.  Itch-in Psoriasis Management.  Curr Probl Dermatol. Basel, Karger,
2016;50:102-10.
van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV.  Scalp psoriasis, clinical presentations 
and therapeutic management.  Dermatology. 1998;197:326-34.
van der Vleuten CJ, van de Kerkhof PC.  Management of scalp psoriasis: guidelines for 
corticosteroid use in combination treatment.  Drugs. 2001;61:1593-8.
Warren RB, Brown BC, Griffiths CE.  Topi[INVESTIGATOR_559724].  Drugs.  
2008;68:2293-302.
CCICCItus.s
ehy EB, hy EB, 
vere psoriasvere psoria
VERVER --2,2,
nstnstititute Incute
r Probl DerProbl De
 Scalp psorScalp pso
326326-34.-34.
ment of scalment of sca
rugsugs..2001;2001
cal treatmecal treatme
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 76 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 201718. APPENDICES
Appendix A: Table of Abbreviations
Table 6: Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term Explanation
ADL Activity of daily life
AE Adverse event
ALT Alanine aminotransferase (SGPT)
ANCOVA Analysis of covariance
AST Aspartate aminotransferase (SGOT)
ATC Anatomical Therapeutic Chemical
BID Twice daily
BMI Body mass index
CI Confidence Interval
CIN Cervical intraepi[INVESTIGATOR_655076]-ROM Compact disc, read only memory device
CIOMS Council for International Organization of Medical Sciences
CMH test Cochran-Mantel-Haenzel test
CO [ADDRESS_879219] radiograph
DLQI Dermatology Life Quality Index
EC Ethics Committee
ECG Electrocardiogram
eCRF Electronic case report form
EMA European Medicines Agency
EOT End of treatment
FAS Full analysis set
FCBP Females of childbearing potential
FDA Food and Drug Administration
CCICCI
CCI&(FASFAS&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7$7$7$70$5025)21),1<5<asiaasia$5memory dememory d7$
ional Organonal Organ([ADDRESS_879220] rad35(DerDem(((31(EE1(1((1((1*(/*OTOT(/&(&
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 77 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 6: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
GCP Good Clinical Practice
GI Gastrointestinal
HDL High-density lipoproteins
HIV Human immunodeficiency virus
HPA Hypothalamic-pi[INVESTIGATOR_2117]-adrenal
HRQoL Health-Related Quality of Life
IB Investigatorâ€™s Brochure
ICF Informed c onsent form
ICH International Council for Harmonisation
IL Interleukin
IND Investigational New Drug
IP Investigational product
IRB Institutional Review Board
IRT Interactive Response Technology
ITT Intent-to-treat
IUD Intrauterine device
LDH Lactate dehydrogenase
LLN Lower level of normal
LOCF Last observation carried forward
LS Least squares
MedDRA Medical Dictionary for Regulatory Activities
MI Multiple imputation
NRI Non-responder imputation
NRS Numeric Rating Scale
PA Posterior to anterior
PDE4 Phosphodiesterase type 4
PP Per protocol
CCICCI
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7$7$7$70$5025)21),1
5<$57$ echnologyechnolog(7,(
vicevice5
ehydrogenashydrogen23r level of nor level of n52Last observaast obser5
Least sqast 3(((1(1(1((1((1*(/*
PAPA&(&&CI((
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 78 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Table 6: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
PUVA Psoralens ultraviolet A
RBC Red blood cell 
SAE Serious adverse event
ScPGA Scalp Physician Global Assessment
SGOT Serum glutamic oxaloacetic transaminase 
SGPT Serum glutamic pyruvic transaminase
SMT Safety Management Team
SOP Standard Operating Procedure
SSC Scientific steering committee
S[LOCATION_003]R Susp ected unexpected serious adverse reaction
TB Tuberculosis
TC Total cholesterol
TEAE Treatment- emergent adverse event
TNF Tumor necrosing factor
TST ([COMPANY_003]) Tuberculin sensitivity test (purified protein derivative)
ULN Upper limit of normal
[LOCATION_003] [LOCATION_002] of America
UV Ultraviolet
UVB Ultraviolet B
WBC White blood cell
WHO World Health Organization
CCICCI
CCI
CCI
&(/*(1(352rculin sensitrculin sensi52Upper limit Upper lim5
United Sited3(UltrUlt(((1(1(1((1((1*(
(/*235,(7$5<,1)250$7,[ZIP_CODE]$7$7$7$70$5025)21),1
5<dverse reactverse rea$57$(7 nt adverse ent adverse e,(
ing factoring factor5
2323
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 79 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix B: Scalp Physician Global Assessment (ScPGA)
Score Category Description
0 ClearScalp Plaque Elevation = 0 (no elevation over normal skin)
Scalp Scaling = 0 (no evidence of scaling)
Scalp Erythema = 0 (except for residual hyperpi[INVESTIGATOR_371]/ 
hypopi[INVESTIGATOR_371])
[ADDRESS_879221] ClearScalp Plaque Elevation = Â± (possible but difficult to ascertain whether 
there is a slight elevation above normal skin)
Scalp Scaling = Â± (surface dryness with some desquamation)
Scalp Erythema = Â± (faint, diffuse pi[INVESTIGATOR_82637])
2 MildScalp Plaque Elevation = slight (slight but definite elevation, typi[INVESTIGATOR_397422])
Scalp Scaling = fine (fine scale partially or mostly covering lesions)
Scalp Erythema = mild (light red coloration)
3 ModerateScalp Plaque Elevation = marked (marked definite elevation with rough 
or sloped edges)
Scalp Scaling = coarser (coarser scale covering most or all of the lesions)
Scalp Erythema = moderate (definite red coloration)
4 SevereScalp Plaque Elevation = marked (marked elevation typi[INVESTIGATOR_655077])
Scalp Scaling = coarser (coarse, non tenacious scale predominates 
covering most or all of the lesions)
Scalp Erythema = severe (very bright red coloration)
CCI&(/*(1([ZIP_CODE],(7$= mmarked (marked (m
arser (coarsarser (coars
r all of the ler all of the l
emama= se= 7$5<,1)250$7,21$7her he
ation)ation)$7$7$7
evation, typevation, typ
tly coveringtly coverin
n)25
ked definiteked definite
scale coveriscale coveri
(definite red(definite red<,
veve7$
23
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 80 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix C: Modified Whole Body Itch Numeric Rating Scale (NRS)
Instruction: Please think about your whole body (including your scalp) when answering the 
question below.
Please rate the itching severity due to your psori asis by [CONTACT_655118] 24 hours.
0        1        2        3        4        5        6        7        8        9        10
0 = No itching 10 = Worst itch imaginable
Naegeli, 2015 .
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21he e
best describest descri
10 = Wo10 = W
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 81 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix D: Scalp Itch Numeric Rating Scale (NRS)
Please rate the itching severity of your scalp due to your psoriasis by [CONTACT_655119] 24 hours .
 
 1R
VFDOS
LWFK :RUVW
VFDOSLWFK
LPDJLQDEOH
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21hat t 

EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 82 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 83 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7,
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 84 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix F: The Dermatology Life Quality Index (DLQI)
The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE 
LAST WEEK.  Please check one box for each question.
2YHUWKHODVWZHHNKRZ itchy, sore, painful RUstinging KDV\RXU
VNLQEHHQ"_ 9HU\PXFK _ $ORW
_ $OLWWOH _ 1RWDWDOO
2YHUWKHODVWZHHNKRZ embarrassed RUself conscious KDYH
\RXEHHQEHFDXVHRI\RXUVNLQ"_ 9HU\PXFK _ $ORW
_ $OLWWOH _ 1RWDWDOO
2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQLQWHUIHUHGZLWK\RX
JRLQJ shoppi[INVESTIGATOR_655078]ORRNLQJDIWHU\RXU home RUyard"_ 9HU\PXFK _ $ORW
_ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW
2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQLQIOXHQFHGWKH
clothes \RXZHDU"_ 9HU\PXFK _ $ORW
_ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW
2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQDIIHFWHGDQ\ social 
RUleisure DFWLYLWLHV"_ 9HU\PXFK _ $ORW
_ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW
2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQPDGHLWGLIILFXOWIR U
\RXWRGRDQ\ sport"_ 9HU\PXFK _ $ORW
_ $OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW
2YHUWKHODVWZHHNKDV\RXUVNLQSUHYHQWHG\RXIURP working RU
studying"_ <HV _ 1R _ 1RWUHOHYDQW
,IÂ³1RÂ´RYHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQEHHQD
SUREOHPDW work RUstudying"_ $ORW _ $OLWWOH _1RW
DWDOO
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,217,$777
$ORW$ORW
RWDWDOORWDWDOO25
_ _ 9HU\PXF9HU\PX
_ _ $OLWWOH$OLW<,
GDQ\GDQ\ socialsocia(7$7$7$
\RXUVNLQPD\RXUVNLQPD23
KDV\RXUVNLQV\RXUVNLQ(3
RYHUWKHODVWZHUWKHODVW
PDPWwork work RR
(/
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 85 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix F: Dermatology Life Quality Index (DLQI) (Continued)
2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQFUHDWHGSUREOHPV
ZLWK\RXU partner RUDQ\RI\RXU close friends RUrelatives"_ 9HU\PXFK _ $ORW _ 
$OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW
2YHUWKHODVWZHHNKRZPXFKKDV\RXUVNLQFDXVHGDQ\ sexual 
difficulties "_ 9HU\PXFK _ $ORW _ 
$OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW
2YHUWKHODVWZHHNKRZPXFKRIDSUREOHPKDVWKH treatment 
IRU\RXUVNLQEHHQIRUH[DPSOHE\PDNLQJ\RXUKRPHPHVV\RU
E\WDNLQJXSWLPH"_ 9HU\PXFK _ $ORW _ 
$OLWWOH _ 1RWDWDOO _ 1RWUHOHYDQW
Finlay, 1994.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,217,
1RWUHOHYDQW1RWUHOHYDQ
25
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 86 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
7,21
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 87 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
21
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 88 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
21
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 89 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
21
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 90 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 91 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,211)250$7,
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 92 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$5<,1)250$7,2
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 93 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017
CCICCI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 94 CC-[ZIP_CODE]-SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix K: Treatment Schema for Dose Titration at Baseline
Dose Day 1 Day 2 Day 3 Day 4 Day 5 Days 6 -7
Group AM PM AM PM AM PM AM PM AM PM AM PM
Placebo 
(dummy 
titration)10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
placebo10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
placebo10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
placebo10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
placebo10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
placebo10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
placebo20 mg 
placebo
+ 30 mg 
placebo20 mg 
placebo
+ 30 mg 
placebo20 mg 
placebo
+ 30 mg 
placebo20 mg 
placebo
+ 30 mg 
placebo20 mg 
placebo
+ 30 mg 
placebo20 mg 
placebo
+ [ADDRESS_879222](titration)[ADDRESS_879223] 
+ 20 mg 
placebo
+ 30 mg 
placebo10 mg 
placebo
+ 20 mg 
placebo
+ [ADDRESS_879224] 
+ 20 mg 
placebo
+ [ADDRESS_879225] + 
20 mg 
placebo
+ 30 mg 
placebo10 mg 
apremilas
t
+ 20 mg 
placebo
+ 30 mg 
placebo10 mg 
placebo
+ [ADDRESS_879226] 
+ [ADDRESS_879227] 
+ [ADDRESS_879228] 
+ [ADDRESS_879229] 
+ 30 mg 
placebo20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ [ADDRESS_879230]
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietetDay 5Day 50$ MM PP55505
boo
0 mg mg 
placeboacebo20 mg 20 mg 
placebp
+ 3+ [ZIP_CODE]
<1)[ADDRESS_879231] 
+ [ADDRESS_879232]<<<
5,((7((5<
EDMS Doc. Number: Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 95 CC-[ZIP_CODE]-SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix L: Treatment Schema for Dose Titration at Week [ADDRESS_879233] 
(titration)10 mg 
apremilas
t + 20 mg 
placebo
+ 30 mg 
placebo10 mg 
placebo
+ 20 mg 
placebo
+ [ADDRESS_879234] 
+ 20 mg 
placebo
+ [ADDRESS_879235] 
+ 20 mg 
placebo
+ [ADDRESS_879236]
+ 20 mg 
placebo
+ 30 mg 
placebo10 mg 
placebo
+ [ADDRESS_879237] 
+ [ADDRESS_879238] 
+ [ADDRESS_879239] 
+ [ADDRESS_879240] 
+ 30 mg 
placebo20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ [ADDRESS_879241]
(dummy 
titration) 10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
apremilas
t10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
apremilast10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
apremilast10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
apremilast10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
apremilast10 mg 
placebo
+ 20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ 30 mg 
apremilast20 mg 
placebo
+ [ADDRESS_879242]
CCI&(/*(1([ZIP_CODE],(7$priprietetsts7$5g
cebobo
[ADDRESS_879243]
(7(7(7(7$5<,1)250$7,21e Corporae Corpora
21
Da$7$7$7$7
PMPM0$$$
5$
bo0 mg m
apremilast apremilast 
+ 30 mg + 30 mg 
placebplac25550
,125
20 mg20 m
placpla
+,1,11
$5,1
EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 96 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix M: Titration Blister Card Configuration
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21

EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 97 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix N: Active Treatment Blister Card Configuration
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21

EDMS Doc. Number:Apremilast
Protocol CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 98 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov 2017Appendix O: Placebo Treatment Blister Card Configuration
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21

EDMS Doc. Number:
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature [CONTACT_13695].
8VHU1DPH
7LWOH'DWH6XQGD\'HFHPEHU30(DVWHUQ'D\OLJKW7LP H
0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
CCI[COMPANY_003]
[COMPANY_003]
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:Apremilast
Summary of Changes CC-[ZIP_CODE]-SPSO-001 Celgene Corporation
Confidential and Propri etary 3 CC-[ZIP_CODE]- SPSO-001 Amendment 1 Final: 30 Nov [ZIP_CODE]. JUSTIFICATION FOR AMENDMENT
Changes included in this amendment are summarized below:
!Modified Section 4.[ADDRESS_879244] 
studies. 
!In Section 6.4 Efficacy Assessment: added inst ructional text to Scalp Physician Global 
Assessment to guide investigators on method of assessment.
!Provided clarification to Section 6.[ADDRESS_879245] documentation of completed TB treatment w ill qualify for 
the study. This is in line with the Exclusion Criteria 8.
!Modified Sections 9.2, 9.5, 11.[ADDRESS_879246] current sponsor standards. 
!Modified Section 8.2 Prohibited Concomitant Medications and Procedures: Topi[INVESTIGATOR_186691]. Replaced acetylsalicylic acid with salicylic acid preparations. This is in line with 
Exclusion Criteria 17.
!Provided updates to the following appendices to reflect the validated and IRB approved
questionnaires that were provided to the subjects since the initiation of the study: 
oAppendix C: Modified Whole Body Itch Numeric Rating Scale;
oAppendix D: Scalp Itch Numeric Rating Scale;
oAppendix F: The Dermatology Life Quality Index;
CCIC
CI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21TB TB 
ualifualifyyffffofor r 
ns to protocns to protoc
oceduresocedur :
aratiarations. ons. ThTh
thhe evalidatva
ce the initce the init iai
NumNum eric Reric 
ing Scaleing Scale
Life Qualitife Quali
35,(235